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Abstract: Introduction. A comprehensive analysis of the immune-cell infiltrate collected from
pleural fluid and from biopsies of malignant pleural mesothelioma (MPM) may
contribute to understand the immune-evasion mechanisms related to tumor
progression, aiding in differential diagnosis and potential prognostic stratification. Till
now such approach has not routinely been verified.
Methods. We enrolled in 275 patients with an initial clinical diagnosis of pleural
effusion. Specimens of pleural fluids and pleural biopsies used for the pathological
diagnosis and the immune-phenotype analyses were blindly investigated by multi-
parametric flow cytometry. The results were analyzed by Kruskal-Wallis test. The
Kaplan-Meier and log-rank tests were used to correlate immune-phenotype data with
patients’ outcome.
Results. The cut-offs of intra-tumor T-regulatory (Treg; >1.1%) cells, M2-macrophages
(>36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; >5.1%
and 4.2%, respectively), CD4+PD1+ (>5.2%) and CD8+PD1+ (6.4%) cells, CD4+LAG-
3+ (>2.8% ) and CD8+LAG-3+ (>2.8%) cells, CD4+TIM-3+ (>2.5%) and CD8+TIM-3+
(>2.6%) cells discriminated MPM from pleuritis with 100% sensitivity and 89%
specificity. The presence of intra-tumor MDSC contributed to the anergy of tumor-
infiltrating lymphocytes (TILs). The immune-phenotype of pleural fluid cells had no
prognostic significance. By contrast, the intra-tumor Treg and MDSC levels significantly
correlated with progression-free and overall survival, the PD-1+/LAG-3+/TIM-3+
CD4+TILs correlated with overall survival.
Conclusions. A clear immune-signature of pleural fluids and tissues of MPM patients
may contribute to better predict patients’ outcome.
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To the attention of  
Prof. Thomas John 
Associate Editor 
Journal of Thoracic Oncology 
 
Dear Professor John, 
We resubmit our manuscript related to the experimental work entitled “Potential diagnostic and 
prognostic role of micro-environment in malignant pleural mesothelioma” (JTO-D-18-01716). 
In accordance with the Reviewers’ comments, we have extensively revised the manuscript and figures. 
A version with changes highlighted in red and a clean version are included. 
We would like to take this opportunity to thank the Reviewers for their valuable comments. The review 
process has contributed to greatly improve the overall quality of the manuscript. 
We hope that the revised version will be suitable for publication in Journal of Thoracic Oncology. 
The presented data were obtained as part of an original research. The manuscript has not been published 
previously and is not being considered concurrently by another journal. 
 
The conflict of interest of each Author has been carefully amended. 
Chiara Riganti 
 
Corresponding author: Dr. Chiara Riganti, Department of Oncology, University of Torino, via 
Santena 5/bis, 10126 Torino, Italy; phone: +39116705857; fax: +39116705845; email: 
chiara.riganti@unito.it 
  
Response to reviewers
Reply to Reviewer 1 
 
Reviewer #1: I reviewed the manuscript by Salaroglio et al on the "Potential diagnostic and predictive 
role of micro-environment in malignant pleural mesothelioma". In their work they look at the 
immunologic micro environment between the pleural effusions or tissue of patients with mesothelioma, 
other cancers or benign effusions. Their work is strengthened by the functional assays; however, there 
are limitations that preclude its publication at this time as described below. 
 
1) Why were both parametric and non-parametric statistics used in a small retrospective cohort. 
Typically, non-parametric statistics are more meaningful in this situation.  
Although we checked the normality distribution of each parameter with the D’Agostino and Pearson 
test, and all parameters had a Gaussian distribution or approximation in pleuritis and pleural malignant 
mesothelioma (MPM) groups, following the Reviewer’s comment, we applied a non-parametric 
(Kruskal Wallis) test to the comparisons. We re-calculated the statistical significance applying this non-
parametric assay (GraphPad PRISM 5.0 software). We modified abstract (page 3, line 4), Materials and 
Methods (page 11, line 2), Figures and legends, accordingly. 
To correlate these values with progression-free survival (PFS) and overall survival (OS), we divided 
the population according to the median value, applying the log-rank test, because there are not 
previously established cut-offs dividing patients with high or low immune-parameters reported in the 
literature and the size of the cohort analyzed was small. 
 
2) How and why were a sample size calculated? This is typically done for prospective trial design, not 
correlative analyses from a retrospective cohort. However, the results of the sample size calculations 
utilized?  
We apologize for not having clearly explained how the sample size was calculated. We modified the 
Materials and Methods section accordingly (page 10, line 20). 
We agree with the Reviewer’s comment that sample size is typically calculated for prospective trial 
design. In our case, sample size was calculated “prospectively” (i.e. before performing the laboratory 
determinations). In detail, before starting the patient enrollment, we calculated the sample size 
necessary to achieve significant results in MPM group, setting significance level (α error probability) < 
0.05, power (1-β error probability) = 0.80, effect size ρ = 0.40, using the G*Power Software 
(www.gpower.hhu.de). The sample size required was 34±2 for MPM group. We thus analyzed 49 
samples from MPM pleural fluid, 33 samples from MPM pleural tissue. The discrepancy between the 
required minimal number of samples (34) and the analyzed samples (49) in the pleural fluid group was 
due to the fact that the pathologists performing the diagnosis and the researchers analyzing the 
immune-infiltrate worked in a blind-manner. The immune-infiltrate analysis was always performed 
before the pathological diagnosis was known. Given the low frequency of MPM, we had to enrolled 
275 patients who received diagnostic thoracoscopies with an initial clinical diagnosis of pleural 
effusion (page 6, line 24), to achieve the required sample size of patients with a confirmed pathological 
diagnosis of MPM. 
 
3) Were other grouping strategies explored other than the median cutoff method described?  
In order to test the association of the immune-parameters analyzed with patients’ outcome (PFS and 
OS), we did not explore grouping strategies other than the division in 2 categories using the median as 
cutoff. In fact, in literature there are no previously reported and validated cut-off the for the immune-
phenotype parameters analyzed. Grouping the patients according to tertiles or quartiles could be 
significantly limited by the small sample size (n=49 MPM derived from pleural fluid; n =33 MPM 
derived from pleural tissue). Indeed dividing by tertiles and quartiles such small cohort, implies a very 
low number of patients (e.g. 3-5) attributed to each subgroup.  
The definition of the optimal cut-off was beyond the scopes of this analysis. A larger prospective study 
is ongoing ay our Institution, with the aim of validating the clinical significance of the immune-
phenotypic signature found in this work. Different grouping strategies will be applied to define in a 
more robust way the correlations between immune-phenotypic parameters, patients clinical history, 
mutational profiling, response to therapy and clinical outcome.  
We modified Material and Methods (page 11, line 8) and Discussion (page 15, line 6; page 17, line 16). 
 
4) For Figures 1-3, Supplemental Figure 3, the labeling is not reader friendly. The values of the 
asterisks, circles or hash symbols change based on the figure, and I cannot always tell what is being 
compared by looking at the figure. 
We reported the statistical significance in uniform way. Asterisks are referred to the comparison of 
MPM or pleural metastases of malignant tumors (MTS) towards pleuritis; circles are referred to the 
comparison of MPM towards MTS (Figure 1-5, new Supplementary Figure 4). In Figure 3, panels D-F, 
hash symbols are referred to the comparison of Gr-MDSC and Mo-MDSC from MPM patients cultured 
with T-cytotoxic lymphocytes from pleuritis patients towards Gr-MDSC and Mo-MDSC from pleuritis 
patients cultured with T-cytotoxic lymphocytes from the same MPM patient.  
We modified the legends of main figures and supplementary figures accordingly.  
 
5) Also, in regards to the figures, since the authors are claiming cut-offs for groups, it would be useful 
to display these results in a format other than bar and line graphs as recommended by statisticians: 
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002128 
Without this type of display, I cannot tell if parametric tests are appropriate since the authors do not 
state that the checked the normality of their data. 
We modified all the bar and line graphs as the Reviewer suggested, using GraphPad PRISM 5.0 
software. To allow a better visualization of the cut-off mentioned in the text, we added them in Figure 1 
(panels D, F), Figure 2 (panels B, D, F, H), new Supplementary Figure 5 (panels A-F).  
We checked the normality of our data by applying the D’Agostino and Pearson test. The results are 
reported in the Table below.  
 
 Normality distribution results 
Figure 1 pleuritis fluid pleuritis tissue MPM fluid MPM tissue MTS fluid MTS tissue 
A 
Yes Yes Yes Yes Yes too small 
B 
Yes Yes Yes Yes Yes too small 
C 
No Yes Yes Yes Yes too small 
E 
Yes Yes Yes Yes Yes too small 
Figure 2       
A 
No No Yes Yes Yes too small 
C 
No Yes Yes Yes Yes too small 
E 
No Yes Yes Yes Yes too small 
G 
No Yes Yes No No too small 
Figure 3       
A 
Yes Yes Yes Yes too small too small 
B 
Yes Yes Yes Yes too small too small 
C 
No Yes Yes Yes too small too small 
D 
Yes Yes Yes Yes too small too small 
E 
Yes Yes Yes Yes too small too small 
F 
Yes No Yes Yes too small too small 
Figure 4       
A 
Yes No Yes No Yes No 
B 
Yes Yes Yes No too small too small 
C 
Yes No Yes Yes Yes Yes 
D 
Yes No Yes No too small too small 
E 
Yes No Yes No Yes No 
F 
Yes No Yes Yes too small too small 
G 
Yes Yes Yes Yes Yes No 
H 
Yes Yes Yes Yes Yes No 
Figure 5       
A 
 Yes  Yes  Yes 
B 
 Yes  Yes  Yes 
C 
 No  Yes  Yes 
D 
 No  Yes  No 
Figure S1A 
No No Yes No Yes too small 
Figure S1A 
No Yes No No No too small 
Figure S2 
Yes Yes Yes Yes No too small 
Figure S3 
Yes Yes Yes Yes No too small 
 
We added a statement on the normality test used in the Materials and Methods (page 11, line 1). 
However, as previously specified, following Reviewer’s comment, we conservatively decided to 
perform non–parametric tests.  
 
6) The conclusion that MDSCs are the primum movens of MPM is far too strong since there are no 
models to demonstrate that they are necessary and sufficient to drive immunosuppression in this 
malignancy. Previously published data on PD-L1 expression suggest that this immune checkpoint is 
also a significant driver with prognostic significance. 
We agree with the Reviewer’s criticism, since our experiments prove that MDSC play an important 
role but are not the only necessary and sufficient finding to determine immune-suppression in MPM. 
We smoothened the sentence commenting our data on MDSC role (Discussion, page 16, line 5). We 
already mentioned the role of PD-L1 as a mediator of immune-suppression and as a marker of poor 
prognosis in MPM (Introduction, page 5, line 20; references 11, 12, 31 and 32 in the previous version, 
references 20, 21, 22, 23 in the revised version).  
 
7) Also, I think it is too strong of the conclusion that the cut offs presented can be used to differentiate 
the groups of patients included in the study. Without discovery and validation cohorts, these 
conclusions cannot be made. The concluding paragraph about using these values to differentiate 
challenging clinical cases cannot stand as written. 
We recognize that we cannot propose the cut-off identified in our study as means to differentiate the 
patients’ groups. As specified above, a larger prospective study, including a discovery and validation 
cohort, is ongoing to evaluate the potential use of the immune-phenotypic signature identified to 
differentiate the challenging clinical cases.  
We rewrote the final paragraph accordingly (page 16, line 17).  
 
8) The authors do not account for multiplicity. So many statistical test were performed yet know 
adjustments were made for the large number of comparisons performed. There are either needs to be 
an explanation for why no adjustments were made or a more stringent P value needs to be applied. 
Given the exploratory nature of the study, we did not make adjustments.  
Following the Reviewer suggestion, we applied a more stringent p value (p<0.01 instead of p<0.05), to 
account, at least partially, for the multiplicity of tests. Only the analysis of survival, considering its 
exploratory nature, was performed with a p<0.05 cutoff.  
We re-calculated the statistical significance with this cut-off and modified Figures and Materials and 
Methods (page 11, lines 5 and 14) accordingly. 
 
9) Finally, the use of "predictive" in the title is not appropriate. Predictive markers suggest which 
patients would benefit from therapy. Whereas prognostic markers are suggestive of survival outcomes. 
We modified the title changing “predictive” role into “prognostic role”. 
 
Minor 
1. The use of some abbreviations is not common, such as PD-1L 
We checked the abbreviations. In particular we corrected the abbreviation PD-1L into PD-L1. 
 
2. Copy editing would help with spelling and grammar (page 5, line 44, "maaged") 
We checked spelling and grammar throughout the manuscript. 
 
Reply to Reviewer 2 
 
Reviewer #2: In this, the age of immunotherapy a comprehensive knowledge of the immune-evasion 
mechanisms has the potential to discover parameters related to tumour progression and 
prognostication. FACS assessment of TILs provides a detailed description of T cell subsets, their 
differentiation and immune checkpoint expression. In this paper by Prof. Riganti et al, the authors have 
conducted a broad explorative analysis on the immune microenvironment of pleural fluid and pleural 
biopsy specimens of patients with suspected mesothelioma. They uncovered some features in the 
immune profile that may potentially be of use in differentiating mesothelioma from pleuritis and 
secondary deposits in the pleura They found a prognostic role for intra-tumor Treg and MDSC levels 
and PD-1+/LAG-3+/TIM-3+ CD4+TILs. Immune-phenotype of pleural fluid cells showed no 
prognostic significance. 
 
The authors are to be congratulated for their exhaustive effort and a well written manuscript. 
 
I think this paper helps further define the immune evasive environment in mesothelioma and sheds 
some light on the prime roles of MDSC and tumour associated macrophages. More importantly, it 
helps delineate the differences in the immune microenvironment in mesothelioma versus pleuritis. This 
could be helpful in the diagnosis of difficult cases. I do however think that the latter findings need to 
validated in larger independent cohorts. 
 
Some points to clear out: 
1) A flow chart (perhaps in the supplemental data section) showing the number of samples collected, 
the numbers included and reason/s for exclusion would be very helpful as this information is not clear. 
Was the collection of samples prospective? Was there a reason why only a proportion had both pleural 
fluid and tissue available for analysis? 
Following the Reviewer’s suggestion, we added a flow chart (new Supplementary Figure 1) and we 
added the missing information about collecting and processing samples (page 6, line 24), and inclusion 
criteria (page 8, line 22), in the revised manuscript.  
We enrolled 275 patients with an initial clinical diagnosis of pleural effusion of unknown origin. The 
patients enrollment was terminated when we reach a sample size with an adequate power in the MPM 
patient cohort (see reply to Reviewer 1, point 2).  
Two aliquots of pleural fluid and pleural tissue were collected by thoracic surgeons at the same time for 
each patient. One aliquot was used for diagnostic purposes according to local pathology guidelines, the 
second one was used for the research study. Priority was given to the diagnostic workup, the left-over 
was dedicated to the research study. On the basis of the pathologists’ decision, in case of limited 
volume of pleural fluid or limited dimension of pleural tissue, both aliquots were dedicated to the 
diagnostic workup. In accordance with the above reported criteria, 183 pleural fluids and 119 pleural 
biopsies were available for the research study. 
The research unit performed a technical feasibility check of the immune-analysis for each sample and 
established to include in the study only samples with > 1×106 viable (i.e. Trypan-blue negative) cells in 
the supernatants or adherent in flask. Preliminary set-up experiments indicated that > 1×106 viable cells 
were the minimal number required allowing to acquire 1×105 cells/staining, to measure each population 
or immune-parameter on each sample. Samples with < 1×106 viable cells were excluded, since they did 
not allow to acquire 1×105 cells/staining. Acquiring < 1×105 cells/staining reduced the accuracy of 
detection of rare immune-populations (i.e. < 10% cells present in the immune-infiltrate) or rare 
immune-checkpoints (< 10% positive cells). 
According to this inclusion criterion, from all the collected samples 63 non-malignant pleuritis, 49 
MPM and 32 MTS for pleural fluid; 16 non-malignant pleuritis, 33 MPM and 5 MTS for pleural tissue 
biopsies were included in the present study. 9 patients with diagnosed pleuritis and 20 patients with 
diagnosed MPM group had both pleural fluid and pleural tissue available.  
 
2) Were the arbitrary cut-offs just the medians for each of the parameters? 
The cut-offs indicated in the abstract, in the text and in Figure 1 (panels D, F), Figure 2 (panels B, D, F, 
H), Supplementary Figure 5 (panels A-F), were fixed in order to discriminate patients with MPM from 
patients with pleuritis with the highest sensitivity. Using the established cut-offs, we yielded a 
sensitivity of 100% (i.e. 0% false negative for all the parameters), and a specificity between 89% and 
100% (i.e. 11% false positive for Treg and Mo-MDSC; 0% false positive for all the remaining 
parameters).  
We better specified this point in the Abstract (page 4, line 6) and Materials and Methods (page 11, line 
6). We reported in extenso throughout the Abstract and the Results section all the cut-offs which met 
the sensitivity and specificity criteria indicated above. We reported the cut-off in the figures and figures 
legends, along with the values of false negative, false positive, sensitivity and specificity.  
In Table 1, Supplementary Figures 6, 7 and 8, we used the medians as cut-offs, to group patients with 
“high” or “low” immune-parameters and correlate the meaning of the immune-parameters evaluated 
with PFS and OS, because of the absence of established cut-offs in the literature and the limited sample 
size of the cohort. 
 
3) We know that there is much inter and intra patient variation in the intensity and composition of 
TILs, do the authors believe that this may have an effect on the ability to differentiate different 
mesothelioma samples from pleuritis and secondaries? 
The intra-tumor immune-infiltrate analysis has been performed on a small cohort of MPM (27 
epithelioid MPM, 3 sarcomatous MPM, 3 biphasic MPM). We did not see correlations between 
different intensity/compositions of TILs, different anamnestic features (age, sex, smoking status, 
presence or absence of asbestos exposure, professional or environmental asbestos exposure, 
Supplementary Table 2), different features of MPM samples (e.g. histological type, Supplementary 
Table 2; mutational profile of each patient, not reported in the manuscript).  
We did not divide further the sample into subgroups according to the qualitative and quantitative 
differences in TILs, to investigate if such differences may have an impact on the differential diagnosis 
between each MPM subgroup, pleuritis or MTS. Working with such small number of patients could 
result in statistical biases due to the limited number of patients in each subgroup.  
A larger prospective study is currently ongoing at our Institution. The aims of this prospective study 
are:  
i) to validate the clinical meaning of the immune-phenotypic signature found in this work, defining in a 
more robust way the correlations between immune-phenotypic parameters, anamnestic information of 
the patients, MPM histotypes, mutational profiling, response to therapy and clinical outcome; 
ii) to evaluate if the analysis of the immune-parameters identified in this work may be routinely applied 
in the diagnostic workup to refine the differential diagnosis with pleuritis and MTS. 
We commented this point in the revised manuscript (Discussion, page 17, line 19; page 18, line 6).   
 
4) The prognostic significance of intra-tumor Treg and MDSC levels and PD-1+/LAG-3+/TIM-3+ 
CD4+TILs is interesting. However, it appears that a multivariate analysis was not done? Are we 
reasonably confident that these are independent of factors like tumour histological subtype as we know 
that the immune-microenvironment varies with histology. 
As stated in reply to point 3, we analyzed intra-tumor Treg, MDSC, PD-1+/LAG-3+/TIM-3+ CD4+TILs 
in a small cohort of MPM. We did not plan a multi-parametric analysis, to avoid possible statistical 
biases due to the small size of the subgroups analyzed. However, we agree with the Reviewer that 
multi-parametric analysis will give important information, and we plan to perform such analyses in the 
ongoing multi-center validation study. 
 
Reply to Reviewer 3 
Reviewer #3: Dr. Salaroglio and colleagues have undertaken a thoughtful analysis of the 
microenvironment in pleural fluid. They have identified features of pleural fluid that are potentially 
diagnostic of the etiology of the fluid - pleuritis, mesothelioma, or metastatic malignant disease. I do 
have several constructive comments as below: 
 
1) Please clarify when relative to the clinical course the samples underwent the research testing 
analyses. The text indicates in parallel. Does that mean that samples were not aggregated for batch 
testing? Or, rather each and every time there was an effusion this battery of testing was performed? 
We apologize for not having detailed the clinical course of sample processing. We added the missing 
information about collecting and processing samples (page 6, line 24), and inclusion criteria (page 8, 
line 22) in the revised manuscript. 
We specified that we performed the whole set of tests for each sample and each time (Materials and 
Methods, page 9, line 1). 
 
2) Please include some discussion of the statistical results around the cut-offs described in the results 
section. 
For the detailed explanation on the choice of the cut-offs, please see the replies to Reviewer 2 (point 2) 
and Reviewer 1 (point 3). 
We commented the choice of such cut-offs in the Discussion (page 14, line 23).  
We specified that the aim of the study was to maximize the correct identification of MPM patients, 
accepting the risk to have sporadic cases of pleuritis identified erroneously as MPM. Since all samples 
were subjected to the usual pathological diagnosis, the rare cases of pleuritis erroneously diagnosed as 
MPM - on the basis of immune-phenotyping - could be easily re-verified by the pathologist. The 
analysis of the immune-parameters was not intended to replace the pathological diagnosis. Our aim was 
to propose a set of new tests supporting the pathological diagnosis of MPM and a set of new prognostic 
factors.  
 
3) There are some contextualization errors throughout the manuscript but within the discussion. For 
example, the statement that "ctla-4 is an important therapeutic target" and referencing an older single 
arm study instead of the large randomized placebo-controlled trial of tremelimumab that was negative, 
casts a mistaken impression around the efficacy of CTLA-4 inhibition in mesothelioma. 
We revised the manuscript to avoid contextualization errors. Specifically, we modified the paragraph 
on CTLA-4, including the reference on the more recent randomized placebo-controlled trial of 
tremelimumab (page 5, line 24). 
 
4) The authors suggest use of these immune profiling measures in border line or difficult to analyze 
cases but provide no information regarding inclusion of those sorts of cases in the development of this 
tool. How many of the analyzed specimens were complex or difficult? Were any cases included where 
the standard analysis was inconclusive? To propose using these standards without demonstrating that 
they were derived from similar cases is not appropriate. 
We agree that we cannot state that the immune-profiling can be used in border-line or difficult to 
analyze cases. Indeed, in our study we had no cases where the standard pathological analysis was 
inconclusive. Only ampler prospective study, currently ongoing at our Institution, may include border-
line or difficult to analyze cases and may allow to compare the accuracy of the standard pathological 
diagnosis and of the immune-phenotype analysis in such cases. 
We modified Abstract (page 3, line 15) and Discussion (page 17, line 24) accordingly.  
 
5) Additionally, the entire cohort is described as having suspected mesothelioma. Please clarify what is 
meant by this? This certainly limits the generalizability of the results. 
We apologize for the sentence reported in the materials and Methods of the previous version: 
“From June 2016 through June 2018 we collected 183 consecutive pleural fluids and 119 pleural 
biopsies from 275 patients with suspected MPM” 
that may have induced a misunderstanding. 
Patients who received diagnostic thoracoscopy (n=275) had an initial diagnosis of pleural effusion of 
unknown origin, as reported in the Abstract (page 3, line 1) and Introduction (page 6, line 18) in the 
previous version. The samples were processed by the Pathology Unit for the diagnostic workup and by 
the research unit for the immune-parameters analysis, in a blind manner. The association between 
pathological diagnosis and immune-phenotype analysis was performed during the final data analysis. 
Only samples with a certain pathological diagnosis of non-malignant pleuritis, MPM or pleural MTS of 
other tumors were included in the research study. We clarified this point in the Materials and Methods 
section (page 7, lines 11 and 24).   
 
6) Overall the discussion is too long and includes a great deal of immunology background that should 
be included preferentially in the introduction as it is not specific to the results herein. 
We shortened the Discussion and moved some key immunology background information in the 
Introduction. The References section was modified accordingly. 
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Abstract  
Introduction. A comprehensive analysis of the immune-cell infiltrate collected from pleural 
fluid and from biopsies of malignant pleural mesothelioma (MPM) may contribute to 
understand the immune-evasion mechanisms related to tumor progression, aiding in 
differential diagnosis and potential prognostic stratification. Till now such approach has not 
routinely been verified. 
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Methods. We enrolled in 275 patients with an initial clinical diagnosis of pleural effusion. 
Specimens of pleural fluids and pleural biopsies used for the pathological diagnosis and the 
immune-phenotype analyses were blindly investigated by multi-parametric flow cytometry. 
The results were analyzed by Kruskal-Wallis test. The Kaplan-Meier and log-rank tests were 
used to correlate immune-phenotype data with patients’ outcome. 
Results. The cut-offs of intra-tumor T-regulatory (Treg; >1.1%) cells, M2-macrophages 
(>36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; >5.1% and 
4.2%, respectively), CD4+PD1+ (>5.2%) and CD8+PD1+ (6.4%) cells, CD4+LAG-3+ (>2.8% ) 
and CD8+LAG-3+ (>2.8%) cells, CD4+TIM-3+ (>2.5%) and CD8+TIM-3+ (>2.6%) cells 
discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. The presence of 
intra-tumor MDSC contributed to the anergy of tumor-infiltrating lymphocytes (TILs). The 
immune-phenotype of pleural fluid cells had no prognostic significance. By contrast, the intra-
tumor Treg and MDSC levels significantly correlated with progression-free and overall 
survival, the PD-1+/LAG-3+/TIM-3+ CD4+TILs correlated with overall survival. 
Conclusions. A clear immune-signature of pleural fluids and tissues of MPM patients may 
contribute to better predict patients’ outcome.  
 
Key words: malignant pleural mesothelioma; tumor-infiltrating lymphocytes; T-regulatory 
cells; myeloid-derived suppressor cells; immune checkpoints 
 
Abbreviations: 
DCFDA-AM: 5-(and-6)-chloromethyl-2′,7′-dichlorodihydro-fluorescein diacetate-
acetoxymethyl ester; FBS: fetal bovine serum; Gr-MDSC: granulocytic myeloid-derived 
suppressor cells; HR: hazard ratio; IDO: 2,3-indoleamine dioxygenase; Mo-MDSC: monocytic 
myeloid-derived suppressor cells; MPM: malignant pleural mesothelioma; MTS: metastases; 
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OS: overall survival; PFS: progression free survival; NK: natural killer; NO: nitric oxide; ROS: 
reactive oxygen species; TAM: tumor-associated macrophage; Treg: T-regulatory; TIL: tumor-
infiltrating lymphocyte.   
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Introduction  
Malignant pleural mesothelioma (MPM) is an asbestos-related cancer characterized by a long 
latency.1 It has a low mutational burden and the tumor micro-environment rather than the 
genetic abnormalities in mesothelial cells may contribute to MPM development and 
progression.2 The MPM micro-environment is rich of immune-suppressive and anergic 
immune cells,4-6 such as T-regulatory (Treg),7-8 granulocytic and monocytic myeloid-derived 
suppressor cells (Gr-MDSC/Mo-MDSC)5,7 and M2-polarized tumor associated macrophages 
(TAMs),9 that – together with soluble factors, such as cytokines, chemokines7 and kynurenine, 
the product of 2,3-indoleamine dioxygenase (IDO) enzyme 8 – lead to a poor response to 
immune-therapy.10 
Several cytokines accumulated in the pleural effusion of MPM patients promote the M2 
polarization of macrophages.11,12 M2/M3-macrophages and11,13 Gr-MDSC5 of MPM patients, 
as well as MPM cells14 reduce the proliferation of heterologous CD8+T-lymphocytes, by 
producing immune-suppressive mediators such as reactive oxygen species (ROS), nitric oxide 
(NO) and kynurenine.5,8,15 MDSC are killed by active CD8+T-lymphocytes,16,17 while either 
Treg and MDSC reduce CD8+T-lymphocytes activity5,7,18 and memory CD8+T-lymphocytes 
recruitment,19 inducing a vicious immune-suppressive circle.  
The high expression of immune-checkpoints on T-lymphocytes and of their ligands on MPM 
cell has another crucial role in the MPM-induced anergy of tumor-infiltrating lymphocytes 
(TILs).6 The PD-1/PD-L1 axis is the more extensively studied and the most correlated with 
early progression and shorter survival.3,4,20,21,22,23 LAG-3 and TIM-3 have been detected on 
CD4+ and CD8+TILs24 or in formalin-fixed paraffin embedded samples.25 Despite the high 
inter-patient and intra-sample variability,26 both LAG-3 and TIM-3 contribute to the functional 
exhaustion of TILs. Furthermore CTLA-4 has been investigated as a potential therapeutic target 
in MPM, but the CTLA-4 inhibitor Tremelimumab did not show higher efficacy than placebo 
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in a double blind phase 2 trial, 27 raising concerns about the role of this immune-checkpoint in 
the MPM-induced immune-suppression. 
The dissection of the immune-environment of MPM is quite difficult and has often twisted 
conflicting findings for different reasons. For instance, the number of T-cells and macrophages 
detected in pleural effusion not always mirrors the amount of the same cells infiltrating MPM 
tissue.28 Some studies reported the same immune-signature in the MPM pleural effusion and 
in the peripheral blood,24 while others did not,5 raising concerns about peripheral blood as a 
biological surrogate that reliably reproduces the MPM immune-environment. Indeed, immune 
cells can be continuously exchanged between pleural cavity and tumor tissue, and/or between 
peripheral blood and pleural environment. This dynamic immune-environment leads to an 
inhomogeneous distribution of immune-cells within MPM tissue. Moreover, the immune-
environment is exposed to time-changes related to the natural tumor progression and/or to 
chemotherapy-related effects.28 Also qualitative and quantitative changes in tumor/stroma ratio 
may produce a dramatic rewiring in the MPM-infiltrating immune cell subsets.18 The high 
intra-patient variability, the intra-tumor heterogeneity,29 the different timing of analysis may 
partially justify the divergent results. 
A simultaneous analysis of all the immune-populations detectable in the pleural effusion and 
infiltrating the tissue has never been performed. The present study aims at a comprehensive 
analysis of the immune-infiltrate detected in the pleural fluid and in the biopsies of pleural 
tissue, collected during routine diagnostic procedures from patients with pleural effusions of 
unknown origin, in order to identify an immune-phenotype with diagnostic and prognostic 
value in MPM patients. 
Materials and methods 
Samples collection. From June 2016 through June 2018 we enrolled 275 patients with an initial 
clinical diagnosis of pleural effusion of unknown origin. The enrollment of patients was 
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stopped when we have reached the sample size with an adequate power in the MPM patient 
cohort (see “Statistical analysis” paragraph). Samples were obtained during diagnostic 
thoracoscopies, at the Thoracic Surgery Division of San Luigi Gonzaga Hospital, Orbassano, 
and AOU Città della Salute e della Scienza, Torino, Italy. Two aliquots of pleural fluid and 
pleural tissue were collected by thoracic surgeons at the same time for each patient. Each 
sample was managed by the Pathology Unit of the two Institutions: one aliquot was used for 
diagnostic purposes according to local pathology guidelines, the second one was used for the 
research study here reported. In case of limited volume of pleural fluid or limited dimension of 
pleural tissue, both aliquots were dedicated to the diagnostic workup. In accordance with this 
criterion, 183 pleural fluids and 119 pleural biopsies were available for the research study. 
Within all these samples, 63 pathologically diagnosed non-malignant pleuritis, 49 MPM and 
32 pleural metastases - MTS - of malignant tumors for pleural fluid; 16 non-malignant pleuritis, 
33 MPM and 5 MTS for pleural tissue biopsies met the technical inclusion criteria (see 
“Phenotyping of immune cells” paragraph) and were analyzed in this study. 9 patients with 
pathologically diagnosed pleuritis and 20 patients with pathologically diagnosed MPM had 
both pleural fluid and pleural tissue available for the study. The flow chart of sample collection 
and processing is reported in the Supplemental Figure 1. The characteristics of samples used 
for the immune-phenotyping in the present study are reported in the Supplemental Table 1. 
The anonymized patients’ history (asbestos exposure and smoking status, whenever available), 
the pathological diagnosis and the clinical follow-up (progression free survival, PFS; overall 
survival, OS) of MPM patients, performed at the Thoracic Oncology Unit, San Luigi Gonzaga 
Hospital, are reported in the Supplemental Table 2. All patients with MPM were in advanced 
clinical stage and all were treated with standard cytotoxic chemotherapy according to current 
guidelines.30 The researchers performing the immune-phenotyping analyses reported below 
worked in a blind manner, being unaware of the pathological diagnosis at the time of the assays. 
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The association between pathological diagnosis, immune-phenotype analysis was performed 
during the final data analysis. The Ethics Committee of San Luigi Gonzaga Hospital, 
Orbassano, Italy approved the study (#126/2016). 
Sample processing and mesothelial/tumor histological analysis. 50 ml of pleural fluid were 
centrifuged at 1200×g for 5 min, washed in PBS containing 1 mg/ml ciprofloxacin (Sigma 
Chemicals Co., St. Louis, MO), and re-suspended at 1×106 cells/ml in Ham’s F10 nutrient 
mixture medium (Invitrogen Life Technology, Milano, Italy), supplemented with 10% v/v fetal 
bovine serum (FBS; Sigma Chemicals Co.), 1% v/v penicillin-streptomycin (Sigma Chemicals 
Co.). Tissues were digested in medium containing 1 mg/ml collagenase and 0.2 mg/ml 
hyaluronidase (Sigma Chemicals Co.) for 1 h at 37°C. Cells from pleural fluid and digested 
tissue were seeded in culture flasks (Becton Dickinson, Franklin Lakes, NJ) for 24 h in 
complete medium. After this period, the cells floating in the supernatant, i.e. immune cells in 
the pleural fluid or infiltrating the tissue, were collected, counted and analyzed for their 
immune-phenotype as detailed below. Adherent cells were analyzed for their 
mesothelial/tumor origin: after detaching by gentle scraping, cells were centrifuged at 1200×g 
for 5 min, fixed in 4% v/v formalin at 4 °C overnight and stained with the following antibodies: 
calretinin (Thermo Fisher Scientific, Waltham, MA), Wilms tumor-1 antigen (Thermo Fisher 
Scientific), cytokeratin 5 (Menarini Diagnostics, Bagno a Ripoli, Italy), podoplanin (Dako, 
Santa Clara, CA), pancytokeratin (Dako), epithelial membrane antigen (EMA, Dako), carcino-
embrionic antigen (CEA, Dako), using an automated immunostainer (Benchmark Ventana 
Medical Systems, Tucson, AZ). 
Phenotyping of immune cells. From all the samples available for research purpose, only 
samples with > 1×106 viable (i.e. Trypan-blue negative) cells in the supernatants or adherent 
in flask were included in the analysis. Preliminary set-up experiments indicated that > 1×106 
viable cells was the minimal number required allowing to acquire 1×105 cells/staining, in order 
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to perform the whole set of the immune-phenotyping tests on each sample. Samples with < 
1×106 viable cells were excluded, since they did not allow to acquire 1×105 cells/staining. The 
supernatants were centrifuged at 1200×g for 5 min, the pellet was washed in PBS and re-
suspended in PBS containing 5% v/v FBS. A three- and four-color flow cytometry was 
performed, with the appropriate combinations of antibodies (all diluted 1:10, from Miltenyi 
Biotec, Teterow, Germany if not otherwise specified) against: CD3 (mouse clone REA613), 
CD4 (mouse clone M-T466), CD8 (mouse clone BW135/80) for T-lymphocytes; CD25 (mouse 
clone 4E3), CD127 (mouse clone MB1518C9) for Treg cells; CD56 (mouse clone AF127H3), 
CD335/NKp46 (mouse clone 9E2) for natural killer (NK) cells; CD19 (mouse clone REA675) 
for B-lymphocytes; CD14 (mouse clone TÜK4) and CD68 (mouse clone Y1/82A) for 
monocytes and macrophages; CD68 (mouse clone Y1/82A), CD208 (mouse clone DCN228) 
and Arginase-1 (sheep polyclonal, # IC5868A, R&D Biosystems; Minneapolis, MN) for M2-
polarized macrophages; CD68 (mouse clone Y1/82A), CD86 (mouse, clone FM95) and iNOS 
(rabbit polyclonal, #SPC-1325, StressMark Biosciences Inc., Victoria, Canada) for M1-
polarized macrophages; CD11b (rat clone M1/70.15.11.5), CD14 (mouse clone TÜK4), CD15 
(mouse clone VIMC6) for granulocytic myeloid-derived suppressor cells (Gr-MSDC) and 
monocytic myeloid-derived suppressor cells (Mo-MDSC). In each combination staining, 1×105 
cells were analyzed using a Guava® easyCyte flow cytometer (Millipore, Bedford, MA), 
equipped with the InCyte software. 
Expression of immune-checkpoints and immune-checkpoint ligands. CD3+ cells were 
isolated from 1×106 immune cells of the supernatant of each culture with the Pan T Cell 
Isolation Kit (Miltenyi Biotec.), washed and re-suspended in PBS containing 5% v/v FBS. The 
detection of immune-checkpoints on CD3+ T-lymphocytes and/or immune-checkpoint ligands 
on MPM cells were performed using antibodies for CD279/PD-1 (mouse clone PD1.3.1.3), 
CD223/LAG-3 (clone REA351), CD366/TIM-3 (mouse clone F38-2E2), CD152/CTLA-4 
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(mouse clone BNI3; all diluted 1:10, Miltenyi Biotec.), CD274/PD-1L (1:100, mouse clone 
29E.2A3, BioLegend, San Diego, CA), anti-GAL-9 (mouse, clone 9M1-3, BioLegend). In each 
combination staining 1×105 cells were analyzed using a Guava® EasyCyte flow cytometer 
(Millipore), equipped with the InCyte software. 
MDSC functional properties. ROS were measured using the fluorescent probe 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-
AM), as previously reported.31 The levels of nitrite, the stable derivative of NO, in cell culture 
supernatants were measured by the Griess method.32 The amount of kynurenine was assessed 
by spectrophotometry.33 The results were expressed as nmoles/mg cellular proteins. 
Proliferation and activation of T-lymphocytes co-cultured with MDSC. 1×104 sorted intra-
tissue Gr-MDSC and Mo-MDSC were co-cultured for 6 days at a 1:1 ratio with sorted intra-
tissue CD3+CD8+T-cytotoxic lymphocytes, either autologous or heterologous, as detailed in 
the experimental section, in the presence of anti-CD3/anti-CD28 dynabeads (Invitrogen Life 
Technologies) to activate lymphocytes. The proliferation of T-lymphocytes was assessed by 
adding 1 µCi of [3H]thymidine (PerkinElmer, Waltham, MA) 18 h before the end of the co-
cultures, then harvesting the plates and counting the radioactivity by liquid scintillation count. 
The results were expressed as count per minute (cpm). The percentage of CD8+CD107a+ and 
the production of IFN-γ, considered indexes of activated cytotoxic T-lymphocytes, were 
measured by flow cytometry and ELISA, as reported.14  
Statistical analysis. Before starting the enrollment of patients, the requested number of 
patients in the MPM cohort was calculated using the G*Power Software (www.gpower.hhu.de) 
using the following assumptions: significance level (α error probability) < 0.05, power (1-β 
error probability) = 0.80, effect size ρ = 0.40). With these parameters, the sample size required 
was 34±2 MPM.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
The normality distribution of each parameter analyzed was checked with the D’Agostino and 
Pearson test. All parameters had a Gaussian distribution or approximation. However, the results 
were conservatively analyzed by the non-parametric Kruskal-Wallis test (GraphPad PRISM 
6.0 software). All data in the figures are provided as means±SD. Medians and quartile values 
are reported in the figure legends. In order to partially correct for the multiplicity of tests 
performed, a conservative p<0.01 was considered statistically significant. For each parameter 
specific cut-off discriminating MPM from pleuritis were calculated in order to have a 100% 
sensitivity (0% false negative) and >89% specificity (<11% false positive). To correlate the 
immune-parameters with PFS and OS, since there are no previously reported and validated cut-
off values for the immune-phenotypic parameters analyzed, patients were exploratively divided 
into “low expressing” and “highly expressing” groups, if their value was below or equal/above 
the median value. The Kaplan-Meier method was used to calculate PFS and OS. Log rank test 
was used to compare the outcome of each group as hazard ratio (HR, i.e. risk of patient death). 
Considering the exploratory nature of the survival analysis, no adjustment for multiplicity was 
made, and p<0.05 was considered statistically significant. 
Results 
High T-regulatory cells/high myeloid-derived suppressor cells discriminate malignant 
pleural mesothelioma from inflammatory pleuritis and secondary pleural tumors 
CD3+T-lymphocytes represented the prevalent immune population within pleural fluid or 
pleural tissue, without differences between samples of pleuritis, MPM or MTS (Figure 1A). 
CD3+CD4+T-helper lymphocytes were up to 60% in all the samples, without differences 
between patient subgroups (Figure 1B). CD3+CD8+T-cytotoxic lymphocytes, representing 
approximately 5% of immune cells in pleural fluids from pleuritis, significantly increased in 
MPM and MTS-pleural fluid samples. By contrast they represented up to 50% of TILs in 
pleuritis and significantly decreased in MPM and MTS (Figure 1C). This trend allowed to 
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discriminate pleuritis (all with CD3+CD8+cells <6.3% in pleural fluid) from MPM (all with 
CD3+CD8+cells >25% in pleural fluid) (Figure 1D). T-reg cells were significantly higher in 
both pleural fluid and tissue from MPM patients compared to pleuritis and MTS-derived 
samples (Figure 1E). A cut-off of >1.4% in pleural fluid and >1.1% in pleural tissue Treg cells 
identified 100% (20/20) MPM and excluded 88.8% (8/9) pleuritis (Figure 1F). NK and B-
lymphocytes were poorly represented and did not show any differences among groups 
(Supplemental Figure 2A-B). 
Also monocytes did not differ (Supplemental Figure 3), while pleural fluid and tissue 
macrophages were significantly higher in MPM and MTS-derived samples (Figure 2A). All 
pleuritic samples had <34% macrophages in pleural fluid and <35% in tissue while all MPM 
samples were above these thresholds (Figure 2B). More relevantly the pro-tumorigenic M2-
macrophages were higher in MPM and MTS compared to pleuritis (Figure 2C). According to 
these parameters, a clear separation between pleuritis (100% of patients with M2-macrophages 
<29% in pleural fluid and <36% in pleural tissue) and MPM (100% of patients with M2-
macrophages >41% in pleural fluid and >44% in pleural tissue) was clearly identified (Figure 
2D). Anti-tumorigenic M1-macrophages were lower in both pleural fluid and tissue of MPM 
and MTS compared with pleuritis (Supplemental Figure 4). 
A significantly higher number of Gr-MDSC (Figure 2E) and Mo-MDSC (Figure 2G) in 
pleural fluid and tissue was detected in MPM compared to pleuritis and MTS. A clear threshold 
of 5.1% Gr-MDSC in both pleural fluid and tissue discriminated 100% pleuritis from 100% 
MPM (Figure 2F). A cut-off of >3.6% Mo-MDSC in pleural fluid and >4.2% in pleural tissue 
identified 100% MPM and excluded 88.8% pleuritis (Figure 2H).  
The intratumor myeloid-derived suppressor cells determine T-lymphocytes anergy 
The MDSC isolated from MPM tissue showed increased production of ROS (Figure 3A), NO 
(Figure 3B) and kynurenine (Figure 3C), compared to those obtained from tissue biopsies of 
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other subgroups. In co-culture with CD8+T-cytotoxic lymphocytes from the tissue of the same 
patient, both Gr-MDSC and Mo-MDSC derived from MPM reduced CD8+T-lymphocytes 
proliferation (Figure 3D), CD107a positivity (Figure 3E) and IFN-γ production (Figure 3F), 
compared to the autologous CD8+T-lymphocytes/MDSC-co-cultures derived from the pleuritis 
and MTS subgroups. The immune-suppressive properties of either Gr-MDSC and Mo-MDSC 
were further demonstrated by co-incubating Gr-MDSC and Mo-MDSC derived from MPM 
tissue with heterologous T-lymphocytes derived from patients with pleuritis. In this setting, 
proliferation, CD107a positivity and IFN-γ production of T-lymphocytes derived from pleuritis 
was reduced to the same level of T-lymphocytes derived from MPM (Figure 3D-F). 
A high number of intra-tumor PD-1+/LAG-3+/TIM-3+ infiltrating lymphocytes is peculiar 
of malignant pleural mesothelioma 
The immune-checkpoints PD-1 (Figure 4A-B), LAG-3 (Figure 4C-D) and TIM-3 (Figure 4E-
F) were higher on CD4+T-helper and CD8+T-cytotoxic lymphocytes of MPM compared to the 
lymphocytes from pleuritis and MTS, either in pleural fluid and in pleural tissue. The cut-off 
values of 6.7% in pleural fluid, 5.2% in pleural tissue for CD4+PD1+ (Supplemental Figure 
5A), 6.3% in pleural fluid, 6.4% in pleural tissue for CD8+PD1+cells (Supplemental Figure 
5B), 4.9% in pleural fluid, 2.8% in pleural tissue for CD4+LAG-3+ (Supplemental Figure 5C), 
5.2% in pleural fluid, 2.8% in pleural tissue for CD8+LAG-3+cells (Supplemental Figure 5D), 
1.9% in pleural fluid, 2.5% in pleural tissue for CD4+TIM-3+ (Supplemental Figure 5E), 2.4% 
in pleural fluid, 2.6% in pleural for CD8+TIM-3+cells tissue (Supplemental Figure 5F), 
discriminated 100% MPM from pleuritis. In our series, the lymphocytic expression of CTLA-
4 did not differ between each subgroup (Figure 4G-H). 
The higher expression of immune-checkpoints on T-lymphocytes was paralleled by the higher 
expression of PD-L1 (Figure 5A), LAG-3 (Figure 5B), TIM-3 (Figure 5C) and GAL-9 
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(Figure 5D) on MPM cells compared to pleuritis and – for LAG-3 and TIM-3 – compared to 
MTS. 
Specific immune-signatures of intratumor infiltrate have a prognostic value 
Furthermore we investigated the potential prognostic role of the immune-phenotypic 
parameters that significantly differed between MPM and pleuritis. 
The amount of CD3+CD8+ cells, Treg, M2-polarized macrophages, Gr/Mo-MDSC, PD-
1+/LAG-3+/TIM3+ CD4+ or CD8+ cells present in the pleural fluids did not show any significant 
correlation with PFS and OS of MPM patients (Table 1). As far as the intratumor immune-
infiltrate was concerned, the amount of CD3+CD8+ cells and M2 were not associated with any 
prognostic significance, while high intratumor Treg, Gr-MDSC and Mo-MDSC significantly 
correlated with shorter PFS and OS (Table 1; Supplemental Figure 6A-E). The amount of 
PD-1+ and LAG-3+ CD4+ cells correlated with a lower OS (Table 1; Supplemental Figure 
7A-C). The expression of immune-checkpoints on intratumor CD8+ had no prognostic 
significance (Table 1; Supplemental Figure 8A-C). 
Discussion 
Specific immune-phenotypic markers on tissue microarrays20 or fine-needle aspirate24 are 
currently investigated to better characterize the immune-environment of MPM. The present 
study for the first time assessed a comprehensive and multi-parametric analysis of the immune-
infiltrate of either pleural fluid and pleural tissue, performed parallelly to the routine diagnostic 
procedures. Based on flow cytometry assays, our experimental model allows to recover viable 
cells, coupling the phenotypic analysis with functional assays of adaptive immunity. Moreover, 
we detected a quite robust immune-signature that discriminates MPM from pleuritis and from 
pleural metastases secondary to other malignancies. By selecting specific cut-offs for each 
immune-parameter analyzed with 100% sensitivity and >89% good specificity, we maximized 
the possibility to identify correctly all the MPM patients, accepting the possibility to have 
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sporadic cases of pleuritis erroneously identified as MPM. Since all samples were subjected to 
the usual pathological diagnosis, the rare cases of pleuritic erroneously identified as MPM on 
the basis of immune-phenotype analysis could be easily re-verified by the pathologist and/or 
clinically followed-up more strictly . The analysis of the immune-parameters was not intended 
to replace the pathological diagnosis but simply to complement the pathological diagnosis of 
MPM with a set of immunological tests and potential new prognostic information. Each 
parameter was indeed correlated with PFS or OS, exploratively using the median values as cut-
off since in literature there are no previously reported and validated cut-offs for the parameters 
analyzed and the identification of the optimal cutoff was beyond the scope of this analysis.  
The first relevant finding discriminating MPM from non-malignant pleuritis was the higher 
intra-pleural fluid CD8+T-lymphocytes coupled with the lower intra-pleural CD8+TILs. The 
amount of CD8+TILs has been associated with adverse18,34 or good 20 prognosis, but in our case 
series, we did not detect any prognostic significance. It is likely that - more than the absolute 
number of CD8+T-lymphocytes - their functional exhaustion, due to the presence of Treg cells 
and MDSC,7,18 is critical in determining tumor progression and patients’ outcome.  
We identified high Treg cells within pleural fluid and tissue as specific biomarkers of MPM 
rather than of benign pleural disease or pleural MTS. The high intra-MPM Treg was a negative 
prognostic factor, while the amount of Treg in pleural fluid had no clinical significance, as 
reported previously.18 This data pointed out that the intratumor immune-infiltrate – more than 
the immune-population in the pleural effusion – in this case is more reliable in predicting the 
patients’ outcome.  
As expected, we did not detect significant differences in overall TAMs between MPM and 
metastatic patients. Compared to pleuritis, M2-macrophages were increased in both tumor and 
pleural fluid of MPM. The correlations between the number of TAMs or the ratio M2/TAM 
and the tumor progression or patients’ outcomes 9,18,20,34 are highly discordant. According to 
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our data M2 percentage is not a significant predictor of patients’ outcome but it is an immune-
marker highly differentiating MPM from non-malignant conditions, as Gr-MDSC and – to a 
lesser extent – Mo-MDSC.  
In our study, Gr- and Mo-MDSC abrogated proliferation and cytotoxic activity of autologous 
TILs and of TILs derived from patients with pleuritis. These data suggest that MDSC mediate 
an important role MPM immune-suppression, likely by the increased production of ROS, NO 
and kynurenine. Again, only the intratumor-infiltrating MDSC - and not the MDSC of pleural 
fluid - are significantly associated with poorer PFS and OS. Taking into consideration the 
dynamic exchange occurring between pleural fluid and tumor,28 pleural fluid can be considered 
as a reservoir of immune-suppressive cells: higher is their migration from pleural fluid into the 
tumor, higher is the chance to characterize an immune-escape status and predict tumor 
progression.  
Immune-checkpoints expression are other key players of immune-suppression in MPM. The 
immunohistochemical expression of PD-L1 and PD-1 is not always reliable as biomarker in 
discriminating pleuritis from MPM: PD-L1 expression was absent in benign lesions, but PD-1 
resulted more expressed on TILs of non-tumoral samples than in TILs of MPM analyzed by 
immunohistochemistry,23 a finding contrasting with the high percentage of PD-1+cells reported 
in MPM using flow cytometry.3,4,6 The type of diagnostic antibody and the abundance of the 
immune-infiltrate in the examined sample may explain this discrepancy. The multi-parametric 
flow cytometry analysis revealed that the amount of PD-1 expressed in CD4+ and CD8+T-
lymphocytes well discriminates MPM from non-malignant pleuritis, but not from metastatic 
cancers, in line with the observation that pleural effusion from lung cancer are also rich of 
PD1+CD8+T-lymphocytes and PD-L1+-cancer cells.35  
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Our data indicate that the expression of PD-1, LAG-3 and TIM-3 in TILs, but not in T-cells in 
pleural effusion, correlated with lower OS. The lack of correlation between immune-
checkpoint levels and PFS likely suggests that the accumulation of immune-checkpoint-
positive, anergic lymphocytes occurs at advanced stages in MPM patients and determines 
prognosis in the terminal stages only. More interestingly, only PD-1+/LAG-3+/TIM-3+CD4+ 
cells, but not CD8+ cells, were negative prognostic factors. Since CD4+ T-cells are a hub in the 
engagement of other immune populations, we may hypothesize that a loss of function of CD4+ 
T-lymphocytes impairs the immune-recognition of MPM cells more than a dysfunction in the 
effector CD8+ T-cells, leading to faster progression and reduced survival. Among the immune-
checkpoints analyzed in MPM patients, CTLA-4 was poorly expressed on the surface of T-
lymphocytes. This is likely related to the cytosol localization of CTLA-4 and the high recycling 
rate.36 Our data need to be re-assessed when a staining optimization for intracellular CTLA-4 
antigen will be achieved. 
In conclusion, we propose a comprehensive multi-parametric analysis of several 
immunological parameters that define a MPM immune-signature, reliably applied to both 
pleural fluid and tissue routinely collected in standard clinical practice. We are aware that our 
discriminating cut-off values, although significant, have been obtained in a small patient 
cohort, and we emphasize that the identification of the optimal cutoff was beyond the scope of 
this analysis. The parameters are now being validated in a larger prospective study, including 
discovery and validation cohorts, in order to improve the specificity of the proposed thresholds 
and evaluate the possible clinical utility of the immune-parameters found. In such ongoing 
study, refined grouping strategies will be adopted, in order to define more accurately the 
quantitative values of the immune-phenotypic parameters significantly correlated with patient 
survival and other clinical parameters. Only if the validation study will confirm this pilot 
experience, the immune biomarkers identified in the present study may be considered as 
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additional parameters to be analyzed - beyond the parameters already adopted to perform MPM 
diagnosis - in challenging clinical cases.  
Of note, this study is the first one aimed to systematically characterize the immune-infiltrate of 
pleural fluid and tumor derived from the same patient. Our results indicated that the analysis 
of the intratumor immune-infiltrate – better than that of pleural fluid – identifies potential 
prognostic factors. Given the high inter-patients and intra-patients variability observed in 
MPM, the larger prospective validation study will also clarify if the qualitative and quantitative 
differences in the intra-tumor immune-infiltrate may be correlated with specific histological, 
cyto-genetic and mutational features. This may contribute to a more accurate patients’ 
stratification, for a rationale and personalized immune-therapy of MPM.    
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Figure legends 
Figure 1. Lymphocyte subtypes present in pleural fluid and tissue of malignant pleural 
mesothelioma 
Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural 
mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from 
digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) 
were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same 
patients were analyzed in parallel. A-C. Percentage of total (CD3+), T-helper (CD3+CD4+)  and 
T-cytotoxic (CD3+CD8+) lymphocytes. Data are presented as means±SD. Values of 25th 
percentile, median, 75th percentile: pleuritis PF: 52.00, 61.00, 66.00; pleuritis PT: 15.00, 21.00, 
26.75; MPM PF: 52.00, 62.00, 71.00; MPM PT: 37.75, 47.00, 58.75; MTS PF: 51.00, 55.00, 
64.00; MTS PT: 36.50, 41.00, 51.50 (panel A); pleuritis PF: 39.25, 52.00, 60.50; pleuritis PT: 
51.00, 61.00, 67.00; MPM PF: 48.25, 61.00, 70.25; MPM PT: 51.00, 56.00, 71.00; MTS PF: 
45.10, 51.50, 60.50; MTS PT: 54.00, 61.00, 67.50 (panel B); pleuritis PF: 2.90, 3.75, 5.98; 
pleuritis PT: 30.00, 41.00, 49.00; MPM PF: 25.00, 29.00, 33.00; MPM PT: 12.00, 15.00, 19.00; 
MTS PF: 14.50, 20.00, 26.00; MTS PT: 10.50, 11.00, 15.50 (panel C). ***p<0.001: 
MPM/MTS vs pleuritis; not significant: MPM vs MTS. D. Disaggregated data of T-cytotoxic 
cells percentage in PF and PT from the same patient. Dotted line: 6.3% cut-off value in PF 
(false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). E. Percentage of 
T-regulatory (Treg; CD4+ CD25+CD127low) cells. Data are presented as means±SD. Values of 
25th percentile, median, 75th percentile: pleuritis PF: 0.90, 1.20, 1.50; pleuritis PT: 0.30, 0.50, 
0.90; MPM PF: 2.73, 2.95, 3.48; MPM PT: 2.10, 2.80, 3.25; MTS PF: 1.10, 1.25, 1.50; MTS 
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PT: 0.75, 1.10, 1.25. ***p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS. 
F. Disaggregated data of Treg cells percentage in PF and PT from the same patient. Dotted 
line: 1.4% cut-off value in PF; dashed line: 1.1% cut-off value in PT (false negative: 0%; false 
positive: 11%; sensitivity: 100%; specificity: 89%) 
Figure 2. Macrophage and myeloid-derived suppressor cell subtypes present in pleural 
fluid and pleural tissue of malignant pleural mesothelioma 
Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural 
mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from 
digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) 
were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same 
patients were analyzed in parallel. A. Percentage of macrophages (CD14+CD68+ cells). Data 
are presented as means±SD. Values of 25th percentile, median, 75th percentile: pleuritis PF: 
15.00, 19.00, 31.00; pleuritis PT: 21.00, 25.00, 32.00; MPM PF: 49.25, 61.00, 71.00; MPM 
PT: 41.75, 55.00, 62.25; MTS PF: 48.25, 54.00, 66.25; MTS PT: 48.50, 65.00, 69.50. *p<0.01, 
***p<0.001: MPM/MTS vs pleuritis. B. Disaggregated data of macrophage percentage in PF 
and PT from the same patient. Dotted line: 34% cut-off value in PF, dashed line: 35% cut-off 
value in PT (false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). C. 
Percentage of M2-macrophages (CD68+CD206+Arg1+cells). Data are presented as means±SD. 
Values of 25th percentile, median, 75th percentile: pleuritis PF: 17.25, 22.00, 28.00; pleuritis 
PT: 23.00, 28.00, 34.50; MPM PF: 45.00, 55.00, 62.25; MPM PT: 56.00, 60.00, 68.25; MTS 
PF: 41.25, 44.00, 57.00; MTS PT: 53.00, 64.00, 65.00. ***p<0.001: MPM/MTS vs pleuritis. 
D. Disaggregated data of M2-macrophage percentage in PF and PT from the same patient. 
Dotted line: 29% cut-off value in PF, dashed line:  36% cut-off value in PT (false negative: 
0%; false positive: 0%; sensitivity: 100%; specificity: 100%). E. Percentage of granulocytic 
myeloid-derived suppressor cells (Gr-MDSC; CD11b+CD14-CD15+cells). Data are presented 
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as means±SD. Values of 25th percentile, median, 75th percentile: pleuritis PF: 2.20, 2.80, 3.68; 
pleuritis PT: 2.10, 2.60, 3.10; MPM PF: 11.23, 13.05, 17.73; MPM PT: 11.80, 13.15, 17.03; 
MTS PF: 3.28, 5.15, 6.30; MTS PT: 4.80, 5.10, 7.70. ***p<0.001: MPM vs pleuritis; 
°°°p<0.001: MPM vs MTS. F. Disaggregated data of Gr-MDSC percentage in PF and PT from 
the same patient. Dashed line: 5.1% cut-off value in PF and PT (false negative: 0%; false 
positive: 0%; sensitivity: 100%; specificity: 100%). G. Percentage of monocytic myeloid 
derived suppressor cells (Mo-MDSC; CD11b+CD14+CD15lowcells). Data are presented as 
means±SD. ***p<0.001: MPM vs pleuritis; °°°p<0.001: MPM vs MTS. Values of 25th 
percentile, median, 75th percentile: pleuritis PF: 2.10, 2.40, 3.45; pleuritis PT: 2.13, 2.75, 3.18; 
MPM PF: 5.90, 8.20, 10.20; MPM PT: 8.10, 9.75, 11.28; MTS PF: 1.30, 2.30, 2.90; MTS PT: 
1.90, 2.35, 2.80. H. Disaggregated data of Mo-MDSC percentage in PF and PT from the same 
patient. Dotted line: 3.6% cut-off value in PF, dashed line: 4.2% cut-off value in PT (false 
negative: 0%; false positive: 11%; sensitivity: 100%; specificity: 89%). 
Figure 3. Intratumor myeloid-derived suppressor cells determines CD8+ T-lymphocytes 
anergy 
1×104 sorted intra-tissue Gr-MDSC and Mo-MDSC derived from pleuritis (n=10), MPM 
(n=12) and other tumors metastatizing to pleura (MTS; n=4) were seeded and analyzed after 
24 h (panels A-C), or co-cultured (panels D-F) for 6 days with the sorted intra-tissue 
CD3+CD8+T-cytotoxic lymphocytes of the corresponding patient (autologous setting). When 
indicated, Gr-MDSC and Mo-MDSC from MPM patients were cultured with T-cytotoxic 
lymphocytes from pleuritis patients (pleu/MPM setting; n=8). A-C. Intracellular ROS (panel 
A) were measured fluorimetrically, nitrite (panel B) and kynurenine (panel C) released in the 
supernatants were measured spectrophotometrically. Data are presented as means±SD. Values 
of 25th percentile, median, 75th percentile: pleuritis Gr-MDSC: 0.59 0.79, 0.94; pleuritis Mo-
MDSC: 0.43, 0.65, 0.80; MPM Gr-MDSC: 2.08, 2.40, 2.78; MPM Mo-MDSC: 1.78, 2.20, 
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2.68; MTS Gr-MDSC: 0.61, 0.72, 0.81; MTS Mo-MDSC: 0.43, 0.66, 0.82 (panel A); pleuritis 
Gr-MDSC: 1.58, 2.00, 2.45; pleuritis Mo-MDSC: 1.60, 2.10, 2.95; MPM Gr-MDSC: 8.20, 
9.75, 12.25; MPM Mo-MDSC: 6.05, 6.85, 8.55; MTS Gr-MDSC: 1.30, 1.75, 2.65; MTS Mo-
MDSC: 1.63, 2.15, 2.45 (panel B); pleuritis Gr-MDSC: 0.55, 0.72, 0.82; pleuritis Mo-MDSC: 
0.72, 0.87, 1.16; MPM Gr-MDSC: 3.73, 4.14, 4.85; MPM Mo-MDSC: 4.25, 5.26, 5.35; MTS 
Gr-MDSC: 0.59, 0.89, 1.19; MTS Mo-MDSC: 0.78, 1.00, 1.24 (panel C). *p<0.01, **p<0.005, 
***p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM vs MTS. D-F. The 
proliferation of T-cytotoxic lymphocytes (panel D) was measured radiometrically, the 
percentage of CD8+CD107a+lymphocytes (panel E) was measured by flow cytometry, the 
amount of IFN-γ (panel F) in the supernatants was measured by ELISA. The proliferation of 
T-lymphocytes in the absence of anti-CD3/anti-CD28 dynabeads, used as negative control, was 
<3500 cpm for all experimental conditions. Data are presented as means±SD. Values of 25th 
percentile, median, 75th percentile: pleuritis Gr-MDSC: 18.09, 23.12, 26.03; pleuritis Mo-
MDSC: 27.53, 30.4, 34.62; MPM Gr-MDSC:2.42, 4.04, 5.00; MPM Mo-MDSC: 4.03, 5.71, 
6.84; MTS Gr-MDSC: 16.66, 22.69, 28.46; MTS Mo-MDSC: 23.27, 31.72, 33.96; pleu/MPM 
Gr-MDSC: 5.33, 5.80, 7.19; pleu/MPM Mo-MDSC: 6.44, 8.25, 11.70 (panel D); pleuritis Gr-
MDSC:2.08, 2.60, 2.83; pleuritis Mo-MDSC: 2.48, 3.00, 3.25; MPM Gr-MDSC: 0.40, 0.60, 
0.80; MPM Mo-MDSC: 0.45, 0.80, 1.05; MTS Gr-MDSC: 1.95, 2.65, 3.05; MTS Mo-MDSC: 
2.83, 3.05, 3.65; pleu/MPM Gr-MDSC: 0.53, 0.75, 0.80; pleu/MPM Mo-MDSC: 0.40, 0.65, 
0.88 (panel E); pleuritis Gr-MDSC: 409.50, 441, 636.50; pleuritis Mo-MDSC: 459.80, 497.50, 
521.00; MPM Gr-MDSC: 111.80, 151.00, 203.30; MPM Mo-MDSC: 147.00, 177.00, 236.00; 
MTS Gr-MDSC: 322.00, 463.50, 506.80; MTS Mo-MDSC: 373.80, 480.00, 585.50; 
pleu/MPM Gr-MDSC: 168.80, 204.50, 263.80; pleu/MPM Mo-MDSC: 209.80, 298.00, 335.80 
(panel F).**p<0.005, ***p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM 
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vs MTS in autologous settings; #p<0.01, ###p<0.001: pleu/MPM setting vs pleuritis autologous 
setting. 
Figure 4. Immune-checkpoint expression in T-lymphocytes contained in pleural fluid and 
pleural tissue 
Cells collected from pleural fluid of patients with pleuritis (n=63), malignant pleural 
mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from 
digested pleural tissue of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) were 
analyzed by flow cytometry. Data are presented as means±SD. A-B. Percentage of PD-1+T-
helper (CD3+CD4+) and T-cytotoxic (CD3+CD8+) lymphocytes. Values of 25th percentile, 
median, 75th percentile: pleuritis CD3+CD4+: 2.45, 4.60, 5.60; pleuritis CD3+CD8+: 2.50, 3.90, 
5.50; MPM CD3+CD4+: 15.53, 18.30, 22.65; MPM CD3+CD8+: 14.83, 17.65, 21.38; MTS 
CD3+CD4+: 7.95, 10.20, 12.30; MTS CD3+CD8+: 7.03, 9.00, 11.33 (panel A); pleuritis 
CD3+CD4+: 2.10, 3.15, 4.10; pleuritis CD3+CD8+: 2.03, 2.90, 4.18; MPM CD3+CD4+: 10.20, 
12.50, 16.15; MPM CD3+CD8+: 11.28, 15.20, 18.05; MTS CD3+CD4+: 3.60, 4.30, 6.50; MTS 
CD3+CD8+: 3.10, 6.20, 8.15 (panel B). ***p<0.001: MPM vs pleuritis; °p<0.01, °°°p<0.001: 
MPM vs MTS. C-D. Percentage of LAG-3+T-helper (CD3+CD4+)  and T-cytotoxic 
(CD3+CD8+) lymphocytes. Values of 25th percentile, median, 75th percentile: pleuritis 
CD3+CD4+: 1.90, 2.80, 4.15; pleuritis CD3+CD8+: 1.90, 2.80, 4.15; MPM CD3+CD4+: 10.83, 
13.35, 16.25; MPM CD3+CD8+: 8.83, 10.60, 14.05; MTS CD3+CD4+: 3.88, 7.20, 8.40; MTS 
CD3+CD8+: 3.75, 7.15, 8.60 (panel C); pleuritis CD3+CD4+: 1.50, 1.85, 2.10; pleuritis 
CD3+CD8+: 1.60, 1.80, 2.18; MPM CD3+CD4+: 8.38, 10.50, 14.28; MPM CD3+CD8+: 8.10, 
10.50, 14.10; MTS CD3+CD4+: 3.40, 4.60, 5.40; MTS CD3+CD8+: 2.95, 4.10, 4.65 (panel D). 
***p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM vs MTS. E-F. 
Percentage of TIM-3+T-helper (CD3+CD4+)  and T-cytotoxic (CD3+CD8+) lymphocytes. 
Values of 25th percentile, median, 75th percentile: pleuritis CD3+CD4+:1, 1.80, 2.48; pleuritis 
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CD3+CD8+: 0.90, 1.35, 1.70; MPM CD3+CD4+: 6.10, 7.30, 8.40; MPM CD3+CD8+: 6.65, 8.30, 
10.70; MTS CD3+CD4+: 2.18, 3.85, 4.43; MTS CD3+CD8+: 1.98, 3.15, 4.13 (panel E); pleuritis 
CD3+CD4+: 1.13, 1.50, 2.05; pleuritis CD3+CD8+: 1.20, 1.35, 1.58; MPM CD3+CD4+: 6.18, 
8.10, 8.53; MPM CD3+CD8+: 6.78, 9.10, 10.20; MTS CD3+CD4+: 1.25, 1.60, 2.20; MTS 
CD3+CD8+: 1.15, 1.40, 1.85 (panel F). ***p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: 
MPM vs MTS. G-H. Percentage of CTLA-4+T-helper (CD3+CD4+)  and T-cytotoxic 
(CD3+CD8+) lymphocytes. Values of 25th percentile, median, 75th percentile: pleuritis 
CD3+CD4+: 1.20, 1.40, 1.90; pleuritis CD3+CD8+: 0.90, 1.30, 1.58; MPM CD3+CD4+: 1.10, 
1.60, 1.90; MPM CD3+CD8+: 1.10, 1.20, 1.50; MTS CD3+CD4+: 1.18, 1.50, 2.10; MTS 
CD3+CD8+: 1.20, 1.30, 1.80 (panel G); pleuritis CD3+CD4+: 1.10, 1.20, 2.05; pleuritis 
CD3+CD8+: 1.25, 1.40, 1.70; MPM CD3+CD4+: 1.30, 1.80, 2.10; MPM CD3+CD8+: 1.20, 1.50, 
1.90; MTS CD3+CD4+: 1.45, 1.70, 2.38; MTS CD3+CD8+: 1.13, 1.40, 1.73 (panel H). 
Figure 5. Immune-checkpoint ligands expressed in malignant pleural mesothelioma cells 
Mesothelial cells collected from patients with pleuritis (n=24), malignant pleural mesothelioma 
cells (MPM; n=33) or cells from different tumors metastatizing to pleura (MTS; n=16), were 
analyzed by flow cytometry for the expression of PD-L1 (panel A), LAG-3 (panel B), TIM-3 
(panel C), GAL-9 (panel D). Data are presented as means±SD. Values of 25th percentile, 
median, 75th percentile: pleuritis: 2.55, 3.60, 4.35; MPM: 15.05, 17.25, 22.95; MTS: 5.60, 9.30, 
12.70 (panel A); pleuritis: 1.43, 1.95, 2.83; MPM: 7.40, 9.10, 11.25; MTS: 2.40, 4.10, 5.10 
(panel B); pleuritis: 1.20, 1.90, 2.73; MPM: 7.35, 8.70, 10.25; MTS: 1.65, 2.40, 5.35 (panel 
C); pleuritis: 1.30, 2.40, 6.23; MPM: 13.40, 17.20, 21.50; MTS: 4.70, 7.80, 9.25 (panel 
D).***p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS.  
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Table 1. Survival analysis according to the immune-phenotypic parameter characterizing 
mesothelioma patients 
Immune-population Sample PFS (months) (95% CI) p value OS (months) (95% CI) p value 
CD3+CD8+ low vs CD3+CD8+ high PF 6.3+1.6  vs 6.3+1.0 (5.0-8.3) 0.913 10.0+2.2  vs 10.8+1.1 (8.2-12.7) 0.6927 
Treg low vs Treg high PF 6.0+1.1  vs 7.0+1.6 (4.7-8.1) 0.496 10.8+1.6  vs 9.7+1.4 (8.2-12.7) 0.4347 
M2 low vs M2 high PF 7.0+1.3  vs 5.7+1.0 (4.7-7.8) 0.2851 10.9+1.5  vs 9.8+1.9 (8.2-12.7) 0.7424 
Gr-MDSC low vs Gr-MDSC high PF 7.1+1.1  vs 5.6+1.3 (4.6-8.1) 0.3351 10.6+1.4  vs 10.8+2.2 (8.2.9-13.1) 0.4522 
Mo-MDSC low vs Mo-MDSC high PF 6.8+1.2  vs 5.9+1.4 (4.4-8.1) 0.8755 10.8+1.6  vs 9.4+1.7 (7.9-12.5) 0.5498 
CD4+PD-1+ low vs CD4+PD-1+ high PF 5.7+1.3  vs 7.3+1.1 (4.7-8.1) 0.713 8.6+1.5  vs 12.4+1.6 (8.2-12.7) 0.1126 
CD4+LAG-3+ low vs CD4+LAG-3+ high PF 7.2+1.4  vs 7.3+1.1 (5.0-8.4) 0.4585 9.6+2.5  vs 10.9+1.1 (8.2-12.7) 0.7886 
CD4+TIM-3+ low vs CD4+TIM-3+ high PF 8.1+1.1  vs 5.0+1.3 (4.9-8.4) 0.1047 11.9+1.2  vs 9.1+2.1 (8.4-12.9) 0.5417 
CD8+PD-1+ low vs CD8+PD-1+ high PF 7.2+1.3  vs 6.8+1.2 (5.3-8.8) 0.6309 9.4+2.0  vs 10.0+1.4 (7.6-11.9) 0.9571 
CD8+LAG-3+ low vs CD8+LAG-3+ high PF 6.5+1.4  vs 4.8+0.8 (4.1-7.2) 0.2127 11.0+1.8  vs 10.1+1.9 (8.1-13.0) 0.8569 
CD8+TIM-3+ low vs CD8+TIM-3+ high PF 7.7+1.1  vs 4.3+1.2 (4.31-7.6) 0.0956 11.0+1.6  vs 9.7+1.6 (8.2-12.3) 0.5441 
CD3+CD8+ low vs CD3+CD8+ high PT 7.4+1.0  vs 8.0+1.3 (6.1-9.2) 0.8624 9.6+1.4  vs 10.3+1.3 (8.3-11.9) 0.9594 
Treg low vs Treg high PT 9.1+1.8  vs 4.7+1.4 (6.1-9.3) 0.0172 12.1+1.2  vs 7.6+1.0 (8.3-11.9) 0.0046 
M2 low vs M2 high PT 7.6+1.7  vs 8.8+1.1 (6.4-10.2) 0.8228 10.4+1.4  vs 9.3+1.2 (8.1-11.7) 0.4016 
Gr-MDSC low vs Gr-MDSC high PT 9.1+1.1  vs 5.6+1.0 (5.9-9.2) 0.0427 11.3+1.3  vs 7.5+1.1 (7.6-11.2) 0.037 
Mo-MDSC low vs Mo-MDSC high PT 11.2+1.2  vs 7.3+1.4 (7.7-11.5) 0.0178 11.1+1.7  vs 8.0+1.0 (8.1-11.4) 0.026 
CD4+PD-1+ low vs CD4+PD-1+ high PT 7.9+1.0  vs 7.9+1.7 (6.2-9.5) 0.6616 11.4+1.1  vs 8.3+1.1 (8.5-11.8) 0.043 
CD4+LAG-3+ low vs CD4+LAG-3+ high PT 8.3+1.1  vs 7.0+1.3 (6.1-9.3) 0.364 11.5+1.4  vs 8.0+0.9 (8.0-11.5) 0.0077 
CD4+TIM-3+ low vs CD4+TIM-3+ high PT 6.8+1.6  vs 8.4+0.9 (6.1-9.4) 0.7595 11.7+1.2  vs 7.8+1.2 (8.0-11.7) 0.044 
CD8+PD-1+ low vs CD8+PD-1+ high PT 7.8+1.3  vs 7.9+1.2 (6.2-9.5) 0.9333 10.3+1.3  vs 10.0+1.2 (8.4-11.8) 0.9315 
CD8+LAG-3+ low vs CD8+LAG-3+ high PT 6.7+1.3  vs 8.0+1.1 (5.7-9.0) 0.6298 9.7+1.5  vs 10.6+1.1 (8.3-11.9) 0.9219 
CD8+TIM-3+ low vs CD8+TIM-3+ high PT 6.8+1.7  vs 8.4+0.8 (6.1-9.3) 0.7423 8.5+1.6  vs 10.6+1.2 (8.0-11.6) 0.574 
The median values of CD3+CD8+ lymphocytes, Treg, M2-macrophages, Gr-MDSC, Mo-
MDSC, CD4+PD-1+, CD4+LAG-3+, CD4+TIM-3+, CD8+PD-1+, CD8+LAG-3+, CD8+TIM-3+ 
cells was calculated in pleural fluid (PF; n=49) and pleural tissue (PT; n=33). Patients were 
classified as “low” or “high” if the percentage of each population was low or equal/higher than 
the median value. Progression free survival (PFS) and overall survival (OS) probability were 
calculated using the Kaplan-Meier method, and expressed as measn±SD (months). CI: 
confidence interval. Significant values are indicated by bold characters.   
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Abstract  19 
Introduction. A comprehensive analysis of the immune-cell infiltrate collected from pleural 20 
fluid and from biopsies of malignant pleural mesothelioma (MPM) may contribute to 21 
understand the immune-evasion mechanisms related to tumor progression, aiding in 22 
differential diagnosis and potential prognostic stratification. Till now such approach has not 23 
routinely been verified. 24 
3 
 
Methods. We enrolled in 275 patients with an initial clinical diagnosis of pleural effusion. 1 
Specimens of pleural fluids and pleural biopsies used for the pathological diagnosis and the 2 
immune-phenotype analyses were blindly investigated by multi-parametric flow cytometry. 3 
The results were analyzed by Kruskal-Wallis test. The Kaplan-Meier and log-rank tests were 4 
used to correlate immune-phenotype data with patients’ outcome. 5 
Results. The cut-offs of intra-tumor T-regulatory (Treg; >1.1%) cells, M2-macrophages 6 
(>36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; >5.1% and 7 
4.2%, respectively), CD4+PD1+ (>5.2%) and CD8+PD1+ (6.4%) cells, CD4+LAG-3+ (>2.8% ) 8 
and CD8+LAG-3+ (>2.8%) cells, CD4+TIM-3+ (>2.5%) and CD8+TIM-3+ (>2.6%) cells 9 
discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. The presence of 10 
intra-tumor MDSC contributed to the anergy of tumor-infiltrating lymphocytes (TILs). The 11 
immune-phenotype of pleural fluid cells had no prognostic significance. By contrast, the intra-12 
tumor Treg and MDSC levels significantly correlated with progression-free and overall 13 
survival, the PD-1+/LAG-3+/TIM-3+ CD4+TILs correlated with overall survival. 14 
Conclusions. A clear immune-signature of pleural fluids and tissues of MPM patients may 15 
contribute to better predict patients’ outcome.  16 
 17 
Key words: malignant pleural mesothelioma; tumor-infiltrating lymphocytes; T-regulatory 18 
cells; myeloid-derived suppressor cells; immune checkpoints 19 
 20 
Abbreviations: 21 
DCFDA-AM: 5-(and-6)-chloromethyl-2′,7′-dichlorodihydro-fluorescein diacetate-22 
acetoxymethyl ester; FBS: fetal bovine serum; Gr-MDSC: granulocytic myeloid-derived 23 
suppressor cells; HR: hazard ratio; IDO: 2,3-indoleamine dioxygenase; Mo-MDSC: monocytic 24 
myeloid-derived suppressor cells; MPM: malignant pleural mesothelioma; MTS: metastases; 25 
4 
 
OS: overall survival; PFS: progression free survival; NK: natural killer; NO: nitric oxide; ROS: 1 
reactive oxygen species; TAM: tumor-associated macrophage; Treg: T-regulatory; TIL: tumor-2 
infiltrating lymphocyte.   3 
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Introduction  1 
Malignant pleural mesothelioma (MPM) is an asbestos-related cancer characterized by a long 2 
latency.1 It has a low mutational burden and the tumor micro-environment rather than the 3 
genetic abnormalities in mesothelial cells may contribute to MPM development and 4 
progression.2 The MPM micro-environment is rich of immune-suppressive and anergic 5 
immune cells,4-6 such as T-regulatory (Treg),7-8 granulocytic and monocytic myeloid-derived 6 
suppressor cells (Gr-MDSC/Mo-MDSC)5,7 and M2-polarized tumor associated macrophages 7 
(TAMs),9 that – together with soluble factors, such as cytokines, chemokines7 and kynurenine, 8 
the product of 2,3-indoleamine dioxygenase (IDO) enzyme 8 – lead to a poor response to 9 
immune-therapy.10 10 
Several cytokines accumulated in the pleural effusion of MPM patients promote the M2 11 
polarization of macrophages.11,12 M2/M3-macrophages and11,13 Gr-MDSC5 of MPM patients, 12 
as well as MPM cells14 reduce the proliferation of heterologous CD8+T-lymphocytes, by 13 
producing immune-suppressive mediators such as reactive oxygen species (ROS), nitric oxide 14 
(NO) and kynurenine.5,8,15 MDSC are killed by active CD8+T-lymphocytes,16,17 while either 15 
Treg and MDSC reduce CD8+T-lymphocytes activity5,7,18 and memory CD8+T-lymphocytes 16 
recruitment,19 inducing a vicious immune-suppressive circle.  17 
The high expression of immune-checkpoints on T-lymphocytes and of their ligands on MPM 18 
cell has another crucial role in the MPM-induced anergy of tumor-infiltrating lymphocytes 19 
(TILs).6 The PD-1/PD-L1 axis is the more extensively studied and the most correlated with 20 
early progression and shorter survival.3,4,20,21,22,23 LAG-3 and TIM-3 have been detected on 21 
CD4+ and CD8+TILs24 or in formalin-fixed paraffin embedded samples.25 Despite the high 22 
inter-patient and intra-sample variability,26 both LAG-3 and TIM-3 contribute to the functional 23 
exhaustion of TILs. Furthermore CTLA-4 has been investigated as a potential therapeutic target 24 
in MPM, but the CTLA-4 inhibitor Tremelimumab did not show higher efficacy than placebo 25 
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in a double blind phase 2 trial, 27 raising concerns about the role of this immune-checkpoint in 1 
the MPM-induced immune-suppression. 2 
The dissection of the immune-environment of MPM is quite difficult and has often twisted 3 
conflicting findings for different reasons. For instance, the number of T-cells and macrophages 4 
detected in pleural effusion not always mirrors the amount of the same cells infiltrating MPM 5 
tissue.28 Some studies reported the same immune-signature in the MPM pleural effusion and 6 
in the peripheral blood,24 while others did not,5 raising concerns about peripheral blood as a 7 
biological surrogate that reliably reproduces the MPM immune-environment. Indeed, immune 8 
cells can be continuously exchanged between pleural cavity and tumor tissue, and/or between 9 
peripheral blood and pleural environment. This dynamic immune-environment leads to an 10 
inhomogeneous distribution of immune-cells within MPM tissue. Moreover, the immune-11 
environment is exposed to time-changes related to the natural tumor progression and/or to 12 
chemotherapy-related effects.28 Also qualitative and quantitative changes in tumor/stroma ratio 13 
may produce a dramatic rewiring in the MPM-infiltrating immune cell subsets.18 The high 14 
intra-patient variability, the intra-tumor heterogeneity,29 the different timing of analysis may 15 
partially justify the divergent results. 16 
A simultaneous analysis of all the immune-populations detectable in the pleural effusion and 17 
infiltrating the tissue has never been performed. The present study aims at a comprehensive 18 
analysis of the immune-infiltrate detected in the pleural fluid and in the biopsies of pleural 19 
tissue, collected during routine diagnostic procedures from patients with pleural effusions of 20 
unknown origin, in order to identify an immune-phenotype with diagnostic and prognostic 21 
value in MPM patients. 22 
Materials and methods 23 
Samples collection. From June 2016 through June 2018 we enrolled 275 patients with an initial 24 
clinical diagnosis of pleural effusion of unknown origin. The enrollment of patients was 25 
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stopped when we have reached the sample size with an adequate power in the MPM patient 1 
cohort (see “Statistical analysis” paragraph). Samples were obtained during diagnostic 2 
thoracoscopies, at the Thoracic Surgery Division of San Luigi Gonzaga Hospital, Orbassano, 3 
and AOU Città della Salute e della Scienza, Torino, Italy. Two aliquots of pleural fluid and 4 
pleural tissue were collected by thoracic surgeons at the same time for each patient. Each 5 
sample was managed by the Pathology Unit of the two Institutions: one aliquot was used for 6 
diagnostic purposes according to local pathology guidelines, the second one was used for the 7 
research study here reported. In case of limited volume of pleural fluid or limited dimension of 8 
pleural tissue, both aliquots were dedicated to the diagnostic workup. In accordance with this 9 
criterion, 183 pleural fluids and 119 pleural biopsies were available for the research study. 10 
Within all these samples, 63 pathologically diagnosed non-malignant pleuritis, 49 MPM and 11 
32 pleural metastases - MTS - of malignant tumors for pleural fluid; 16 non-malignant pleuritis, 12 
33 MPM and 5 MTS for pleural tissue biopsies met the technical inclusion criteria (see 13 
“Phenotyping of immune cells” paragraph) and were analyzed in this study. 9 patients with 14 
pathologically diagnosed pleuritis and 20 patients with pathologically diagnosed MPM had 15 
both pleural fluid and pleural tissue available for the study. The flow chart of sample collection 16 
and processing is reported in the Supplemental Figure 1. The characteristics of samples used 17 
for the immune-phenotyping in the present study are reported in the Supplemental Table 1. 18 
The anonymized patients’ history (asbestos exposure and smoking status, whenever available), 19 
the pathological diagnosis and the clinical follow-up (progression free survival, PFS; overall 20 
survival, OS) of MPM patients, performed at the Thoracic Oncology Unit, San Luigi Gonzaga 21 
Hospital, are reported in the Supplemental Table 2. All patients with MPM were in advanced 22 
clinical stage and all were treated with standard cytotoxic chemotherapy according to current 23 
guidelines.30 The researchers performing the immune-phenotyping analyses reported below 24 
worked in a blind manner, being unaware of the pathological diagnosis at the time of the assays. 25 
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The association between pathological diagnosis, immune-phenotype analysis was performed 1 
during the final data analysis. The Ethics Committee of San Luigi Gonzaga Hospital, 2 
Orbassano, Italy approved the study (#126/2016). 3 
Sample processing and mesothelial/tumor histological analysis. 50 ml of pleural fluid were 4 
centrifuged at 1200×g for 5 min, washed in PBS containing 1 mg/ml ciprofloxacin (Sigma 5 
Chemicals Co., St. Louis, MO), and re-suspended at 1×106 cells/ml in Ham’s F10 nutrient 6 
mixture medium (Invitrogen Life Technology, Milano, Italy), supplemented with 10% v/v fetal 7 
bovine serum (FBS; Sigma Chemicals Co.), 1% v/v penicillin-streptomycin (Sigma Chemicals 8 
Co.). Tissues were digested in medium containing 1 mg/ml collagenase and 0.2 mg/ml 9 
hyaluronidase (Sigma Chemicals Co.) for 1 h at 37°C. Cells from pleural fluid and digested 10 
tissue were seeded in culture flasks (Becton Dickinson, Franklin Lakes, NJ) for 24 h in 11 
complete medium. After this period, the cells floating in the supernatant, i.e. immune cells in 12 
the pleural fluid or infiltrating the tissue, were collected, counted and analyzed for their 13 
immune-phenotype as detailed below. Adherent cells were analyzed for their 14 
mesothelial/tumor origin: after detaching by gentle scraping, cells were centrifuged at 1200×g 15 
for 5 min, fixed in 4% v/v formalin at 4 °C overnight and stained with the following antibodies: 16 
calretinin (Thermo Fisher Scientific, Waltham, MA), Wilms tumor-1 antigen (Thermo Fisher 17 
Scientific), cytokeratin 5 (Menarini Diagnostics, Bagno a Ripoli, Italy), podoplanin (Dako, 18 
Santa Clara, CA), pancytokeratin (Dako), epithelial membrane antigen (EMA, Dako), carcino-19 
embrionic antigen (CEA, Dako), using an automated immunostainer (Benchmark Ventana 20 
Medical Systems, Tucson, AZ). 21 
Phenotyping of immune cells. From all the samples available for research purpose, only 22 
samples with > 1×106 viable (i.e. Trypan-blue negative) cells in the supernatants or adherent 23 
in flask were included in the analysis. Preliminary set-up experiments indicated that > 1×106 24 
viable cells was the minimal number required allowing to acquire 1×105 cells/staining, in order 25 
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to perform the whole set of the immune-phenotyping tests on each sample. Samples with < 1 
1×106 viable cells were excluded, since they did not allow to acquire 1×105 cells/staining. The 2 
supernatants were centrifuged at 1200×g for 5 min, the pellet was washed in PBS and re-3 
suspended in PBS containing 5% v/v FBS. A three- and four-color flow cytometry was 4 
performed, with the appropriate combinations of antibodies (all diluted 1:10, from Miltenyi 5 
Biotec, Teterow, Germany if not otherwise specified) against: CD3 (mouse clone REA613), 6 
CD4 (mouse clone M-T466), CD8 (mouse clone BW135/80) for T-lymphocytes; CD25 (mouse 7 
clone 4E3), CD127 (mouse clone MB1518C9) for Treg cells; CD56 (mouse clone AF127H3), 8 
CD335/NKp46 (mouse clone 9E2) for natural killer (NK) cells; CD19 (mouse clone REA675) 9 
for B-lymphocytes; CD14 (mouse clone TÜK4) and CD68 (mouse clone Y1/82A) for 10 
monocytes and macrophages; CD68 (mouse clone Y1/82A), CD208 (mouse clone DCN228) 11 
and Arginase-1 (sheep polyclonal, # IC5868A, R&D Biosystems; Minneapolis, MN) for M2-12 
polarized macrophages; CD68 (mouse clone Y1/82A), CD86 (mouse, clone FM95) and iNOS 13 
(rabbit polyclonal, #SPC-1325, StressMark Biosciences Inc., Victoria, Canada) for M1-14 
polarized macrophages; CD11b (rat clone M1/70.15.11.5), CD14 (mouse clone TÜK4), CD15 15 
(mouse clone VIMC6) for granulocytic myeloid-derived suppressor cells (Gr-MSDC) and 16 
monocytic myeloid-derived suppressor cells (Mo-MDSC). In each combination staining, 1×105 17 
cells were analyzed using a Guava® easyCyte flow cytometer (Millipore, Bedford, MA), 18 
equipped with the InCyte software. 19 
Expression of immune-checkpoints and immune-checkpoint ligands. CD3+ cells were 20 
isolated from 1×106 immune cells of the supernatant of each culture with the Pan T Cell 21 
Isolation Kit (Miltenyi Biotec.), washed and re-suspended in PBS containing 5% v/v FBS. The 22 
detection of immune-checkpoints on CD3+ T-lymphocytes and/or immune-checkpoint ligands 23 
on MPM cells were performed using antibodies for CD279/PD-1 (mouse clone PD1.3.1.3), 24 
CD223/LAG-3 (clone REA351), CD366/TIM-3 (mouse clone F38-2E2), CD152/CTLA-4 25 
10 
 
(mouse clone BNI3; all diluted 1:10, Miltenyi Biotec.), CD274/PD-1L (1:100, mouse clone 1 
29E.2A3, BioLegend, San Diego, CA), anti-GAL-9 (mouse, clone 9M1-3, BioLegend). In each 2 
combination staining 1×105 cells were analyzed using a Guava® EasyCyte flow cytometer 3 
(Millipore), equipped with the InCyte software. 4 
MDSC functional properties. ROS were measured using the fluorescent probe 5-(and-6)-5 
chloromethyl-2′,7′-dichlorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-AM), 6 
as previously reported.31 The levels of nitrite, the stable derivative of NO, in cell culture 7 
supernatants were measured by the Griess method.32 The amount of kynurenine was assessed 8 
by spectrophotometry.33 The results were expressed as nmoles/mg cellular proteins. 9 
Proliferation and activation of T-lymphocytes co-cultured with MDSC. 1×104 sorted intra-10 
tissue Gr-MDSC and Mo-MDSC were co-cultured for 6 days at a 1:1 ratio with sorted intra-11 
tissue CD3+CD8+T-cytotoxic lymphocytes, either autologous or heterologous, as detailed in 12 
the experimental section, in the presence of anti-CD3/anti-CD28 dynabeads (Invitrogen Life 13 
Technologies) to activate lymphocytes. The proliferation of T-lymphocytes was assessed by 14 
adding 1 µCi of [3H]thymidine (PerkinElmer, Waltham, MA) 18 h before the end of the co-15 
cultures, then harvesting the plates and counting the radioactivity by liquid scintillation count. 16 
The results were expressed as count per minute (cpm). The percentage of CD8+CD107a+ and 17 
the production of IFN-γ, considered indexes of activated cytotoxic T-lymphocytes, were 18 
measured by flow cytometry and ELISA, as reported.14  19 
Statistical analysis. Before starting the enrollment of patients, the requested number of 20 
patients in the MPM cohort was calculated using the G*Power Software (www.gpower.hhu.de) 21 
using the following assumptions: significance level (α error probability) < 0.05, power (1-β 22 
error probability) = 0.80, effect size ρ = 0.40). With these parameters, the sample size required 23 
was 34±2 MPM.  24 
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The normality distribution of each parameter analyzed was checked with the D’Agostino and 1 
Pearson test. All parameters had a Gaussian distribution or approximation. However, the results 2 
were conservatively analyzed by the non-parametric Kruskal-Wallis test (GraphPad PRISM 3 
6.0 software). All data in the figures are provided as means±SD. Medians and quartile values 4 
are reported in the figure legends. In order to partially correct for the multiplicity of tests 5 
performed, a conservative p<0.01 was considered statistically significant. For each parameter 6 
specific cut-off discriminating MPM from pleuritis were calculated in order to have a 100% 7 
sensitivity (0% false negative) and >89% specificity (<11% false positive). To correlate the 8 
immune-parameters with PFS and OS, since there are no previously reported and validated cut-9 
off values for the immune-phenotypic parameters analyzed, patients were exploratively divided 10 
into “low expressing” and “highly expressing” groups, if their value was below or equal/above 11 
the median value. The Kaplan-Meier method was used to calculate PFS and OS. Log rank test 12 
was used to compare the outcome of each group as hazard ratio (HR, i.e. risk of patient death). 13 
Considering the exploratory nature of the survival analysis, no adjustment for multiplicity was 14 
made, and p<0.05 was considered statistically significant. 15 
Results 16 
High T-regulatory cells/high myeloid-derived suppressor cells discriminate malignant 17 
pleural mesothelioma from inflammatory pleuritis and secondary pleural tumors 18 
CD3+T-lymphocytes represented the prevalent immune population within pleural fluid or 19 
pleural tissue, without differences between samples of pleuritis, MPM or MTS (Figure 1A). 20 
CD3+CD4+T-helper lymphocytes were up to 60% in all the samples, without differences 21 
between patient subgroups (Figure 1B). CD3+CD8+T-cytotoxic lymphocytes, representing 22 
approximately 5% of immune cells in pleural fluids from pleuritis, significantly increased in 23 
MPM and MTS-pleural fluid samples. By contrast they represented up to 50% of TILs in 24 
pleuritis and significantly decreased in MPM and MTS (Figure 1C). This trend allowed to 25 
12 
 
discriminate pleuritis (all with CD3+CD8+cells <6.3% in pleural fluid) from MPM (all with 1 
CD3+CD8+cells >25% in pleural fluid) (Figure 1D). T-reg cells were significantly higher in 2 
both pleural fluid and tissue from MPM patients compared to pleuritis and MTS-derived 3 
samples (Figure 1E). A cut-off of >1.4% in pleural fluid and >1.1% in pleural tissue Treg cells 4 
identified 100% (20/20) MPM and excluded 88.8% (8/9) pleuritis (Figure 1F). NK and B-5 
lymphocytes were poorly represented and did not show any differences among groups 6 
(Supplemental Figure 2A-B). 7 
Also monocytes did not differ (Supplemental Figure 3), while pleural fluid and tissue 8 
macrophages were significantly higher in MPM and MTS-derived samples (Figure 2A). All 9 
pleuritic samples had <34% macrophages in pleural fluid and <35% in tissue while all MPM 10 
samples were above these thresholds (Figure 2B). More relevantly the pro-tumorigenic M2-11 
macrophages were higher in MPM and MTS compared to pleuritis (Figure 2C). According to 12 
these parameters, a clear separation between pleuritis (100% of patients with M2-macrophages 13 
<29% in pleural fluid and <36% in pleural tissue) and MPM (100% of patients with M2-14 
macrophages >41% in pleural fluid and >44% in pleural tissue) was clearly identified (Figure 15 
2D). Anti-tumorigenic M1-macrophages were lower in both pleural fluid and tissue of MPM 16 
and MTS compared with pleuritis (Supplemental Figure 4). 17 
A significantly higher number of Gr-MDSC (Figure 2E) and Mo-MDSC (Figure 2G) in 18 
pleural fluid and tissue was detected in MPM compared to pleuritis and MTS. A clear threshold 19 
of 5.1% Gr-MDSC in both pleural fluid and tissue discriminated 100% pleuritis from 100% 20 
MPM (Figure 2F). A cut-off of >3.6% Mo-MDSC in pleural fluid and >4.2% in pleural tissue 21 
identified 100% MPM and excluded 88.8% pleuritis (Figure 2H).  22 
The intratumor myeloid-derived suppressor cells determine T-lymphocytes anergy 23 
The MDSC isolated from MPM tissue showed increased production of ROS (Figure 3A), NO 24 
(Figure 3B) and kynurenine (Figure 3C), compared to those obtained from tissue biopsies of 25 
13 
 
other subgroups. In co-culture with CD8+T-cytotoxic lymphocytes from the tissue of the same 1 
patient, both Gr-MDSC and Mo-MDSC derived from MPM reduced CD8+T-lymphocytes 2 
proliferation (Figure 3D), CD107a positivity (Figure 3E) and IFN-γ production (Figure 3F), 3 
compared to the autologous CD8+T-lymphocytes/MDSC-co-cultures derived from the pleuritis 4 
and MTS subgroups. The immune-suppressive properties of either Gr-MDSC and Mo-MDSC 5 
were further demonstrated by co-incubating Gr-MDSC and Mo-MDSC derived from MPM 6 
tissue with heterologous T-lymphocytes derived from patients with pleuritis. In this setting, 7 
proliferation, CD107a positivity and IFN-γ production of T-lymphocytes derived from pleuritis 8 
was reduced to the same level of T-lymphocytes derived from MPM (Figure 3D-F). 9 
A high number of intra-tumor PD-1+/LAG-3+/TIM-3+ infiltrating lymphocytes is peculiar 10 
of malignant pleural mesothelioma 11 
The immune-checkpoints PD-1 (Figure 4A-B), LAG-3 (Figure 4C-D) and TIM-3 (Figure 4E-12 
F) were higher on CD4+T-helper and CD8+T-cytotoxic lymphocytes of MPM compared to the 13 
lymphocytes from pleuritis and MTS, either in pleural fluid and in pleural tissue. The cut-off 14 
values of 6.7% in pleural fluid, 5.2% in pleural tissue for CD4+PD1+ (Supplemental Figure 15 
5A), 6.3% in pleural fluid, 6.4% in pleural tissue for CD8+PD1+cells (Supplemental Figure 16 
5B), 4.9% in pleural fluid, 2.8% in pleural tissue for CD4+LAG-3+ (Supplemental Figure 5C), 17 
5.2% in pleural fluid, 2.8% in pleural tissue for CD8+LAG-3+cells (Supplemental Figure 5D), 18 
1.9% in pleural fluid, 2.5% in pleural tissue for CD4+TIM-3+ (Supplemental Figure 5E), 2.4% 19 
in pleural fluid, 2.6% in pleural for CD8+TIM-3+cells tissue (Supplemental Figure 5F), 20 
discriminated 100% MPM from pleuritis. In our series, the lymphocytic expression of CTLA-21 
4 did not differ between each subgroup (Figure 4G-H). 22 
The higher expression of immune-checkpoints on T-lymphocytes was paralleled by the higher 23 
expression of PD-L1 (Figure 5A), LAG-3 (Figure 5B), TIM-3 (Figure 5C) and GAL-9 24 
14 
 
(Figure 5D) on MPM cells compared to pleuritis and – for LAG-3 and TIM-3 – compared to 1 
MTS. 2 
Specific immune-signatures of intratumor infiltrate have a prognostic value 3 
Furthermore we investigated the potential prognostic role of the immune-phenotypic 4 
parameters that significantly differed between MPM and pleuritis. 5 
The amount of CD3+CD8+ cells, Treg, M2-polarized macrophages, Gr/Mo-MDSC, PD-6 
1+/LAG-3+/TIM3+ CD4+ or CD8+ cells present in the pleural fluids did not show any significant 7 
correlation with PFS and OS of MPM patients (Table 1). As far as the intratumor immune-8 
infiltrate was concerned, the amount of CD3+CD8+ cells and M2 were not associated with any 9 
prognostic significance, while high intratumor Treg, Gr-MDSC and Mo-MDSC significantly 10 
correlated with shorter PFS and OS (Table 1; Supplemental Figure 6A-E). The amount of 11 
PD-1+ and LAG-3+ CD4+ cells correlated with a lower OS (Table 1; Supplemental Figure 12 
7A-C). The expression of immune-checkpoints on intratumor CD8+ had no prognostic 13 
significance (Table 1; Supplemental Figure 8A-C). 14 
Discussion 15 
Specific immune-phenotypic markers on tissue microarrays20 or fine-needle aspirate24 are 16 
currently investigated to better characterize the immune-environment of MPM. The present 17 
study for the first time assessed a comprehensive and multi-parametric analysis of the immune-18 
infiltrate of either pleural fluid and pleural tissue, performed parallelly to the routine diagnostic 19 
procedures. Based on flow cytometry assays, our experimental model allows to recover viable 20 
cells, coupling the phenotypic analysis with functional assays of adaptive immunity. Moreover, 21 
we detected a quite robust immune-signature that discriminates MPM from pleuritis and from 22 
pleural metastases secondary to other malignancies. By selecting specific cut-offs for each 23 
immune-parameter analyzed with 100% sensitivity and >89% good specificity, we maximized 24 
the possibility to identify correctly all the MPM patients, accepting the possibility to have 25 
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sporadic cases of pleuritis erroneously identified as MPM. Since all samples were subjected to 1 
the usual pathological diagnosis, the rare cases of pleuritic erroneously identified as MPM on 2 
the basis of immune-phenotype analysis could be easily re-verified by the pathologist and/or 3 
clinically followed-up more strictly . The analysis of the immune-parameters was not intended 4 
to replace the pathological diagnosis but simply to complement the pathological diagnosis of 5 
MPM with a set of immunological tests and potential new prognostic information. Each 6 
parameter was indeed correlated with PFS or OS, exploratively using the median values as cut-7 
off since in literature there are no previously reported and validated cut-offs for the parameters 8 
analyzed and the identification of the optimal cutoff was beyond the scope of this analysis.  9 
The first relevant finding discriminating MPM from non-malignant pleuritis was the higher 10 
intra-pleural fluid CD8+T-lymphocytes coupled with the lower intra-pleural CD8+TILs. The 11 
amount of CD8+TILs has been associated with adverse18,34 or good 20 prognosis, but in our case 12 
series, we did not detect any prognostic significance. It is likely that - more than the absolute 13 
number of CD8+T-lymphocytes - their functional exhaustion, due to the presence of Treg cells 14 
and MDSC,7,18 is critical in determining tumor progression and patients’ outcome.  15 
We identified high Treg cells within pleural fluid and tissue as specific biomarkers of MPM 16 
rather than of benign pleural disease or pleural MTS. The high intra-MPM Treg was a negative 17 
prognostic factor, while the amount of Treg in pleural fluid had no clinical significance, as 18 
reported previously.18 This data pointed out that the intratumor immune-infiltrate – more than 19 
the immune-population in the pleural effusion – in this case is more reliable in predicting the 20 
patients’ outcome.  21 
As expected, we did not detect significant differences in overall TAMs between MPM and 22 
metastatic patients. Compared to pleuritis, M2-macrophages were increased in both tumor and 23 
pleural fluid of MPM. The correlations between the number of TAMs or the ratio M2/TAM 24 
and the tumor progression or patients’ outcomes 9,18,20,34 are highly discordant. According to 25 
16 
 
our data M2 percentage is not a significant predictor of patients’ outcome but it is an immune-1 
marker highly differentiating MPM from non-malignant conditions, as Gr-MDSC and – to a 2 
lesser extent – Mo-MDSC.  3 
In our study, Gr- and Mo-MDSC abrogated proliferation and cytotoxic activity of autologous 4 
TILs and of TILs derived from patients with pleuritis. These data suggest that MDSC mediate 5 
an important role MPM immune-suppression, likely by the increased production of ROS, NO 6 
and kynurenine. Again, only the intratumor-infiltrating MDSC - and not the MDSC of pleural 7 
fluid - are significantly associated with poorer PFS and OS. Taking into consideration the 8 
dynamic exchange occurring between pleural fluid and tumor,28 pleural fluid can be considered 9 
as a reservoir of immune-suppressive cells: higher is their migration from pleural fluid into the 10 
tumor, higher is the chance to characterize an immune-escape status and predict tumor 11 
progression.  12 
Immune-checkpoints expression are other key players of immune-suppression in MPM. The 13 
immunohistochemical expression of PD-L1 and PD-1 is not always reliable as biomarker in 14 
discriminating pleuritis from MPM: PD-L1 expression was absent in benign lesions, but PD-1 15 
resulted more expressed on TILs of non-tumoral samples than in TILs of MPM analyzed by 16 
immunohistochemistry,23 a finding contrasting with the high percentage of PD-1+cells reported 17 
in MPM using flow cytometry.3,4,6 The type of diagnostic antibody and the abundance of the 18 
immune-infiltrate in the examined sample may explain this discrepancy. The multi-parametric 19 
flow cytometry analysis revealed that the amount of PD-1 expressed in CD4+ and CD8+T-20 
lymphocytes well discriminates MPM from non-malignant pleuritis, but not from metastatic 21 
cancers, in line with the observation that pleural effusion from lung cancer are also rich of 22 
PD1+CD8+T-lymphocytes and PD-L1+-cancer cells.35  23 
17 
 
Our data indicate that the expression of PD-1, LAG-3 and TIM-3 in TILs, but not in T-cells in 1 
pleural effusion, correlated with lower OS. The lack of correlation between immune-2 
checkpoint levels and PFS likely suggests that the accumulation of immune-checkpoint-3 
positive, anergic lymphocytes occurs at advanced stages in MPM patients and determines 4 
prognosis in the terminal stages only. More interestingly, only PD-1+/LAG-3+/TIM-3+CD4+ 5 
cells, but not CD8+ cells, were negative prognostic factors. Since CD4+ T-cells are a hub in the 6 
engagement of other immune populations, we may hypothesize that a loss of function of CD4+ 7 
T-lymphocytes impairs the immune-recognition of MPM cells more than a dysfunction in the 8 
effector CD8+ T-cells, leading to faster progression and reduced survival. Among the immune-9 
checkpoints analyzed in MPM patients, CTLA-4 was poorly expressed on the surface of T-10 
lymphocytes. This is likely related to the cytosol localization of CTLA-4 and the high recycling 11 
rate.36 Our data need to be re-assessed when a staining optimization for intracellular CTLA-4 12 
antigen will be achieved. 13 
In conclusion, we propose a comprehensive multi-parametric analysis of several 14 
immunological parameters that define a MPM immune-signature, reliably applied to both 15 
pleural fluid and tissue routinely collected in standard clinical practice. We are aware that our 16 
discriminating cut-off values, although significant, have been obtained in a small patient 17 
cohort, and we emphasize that the identification of the optimal cutoff was beyond the scope of 18 
this analysis. The parameters are now being validated in a larger prospective study, including 19 
discovery and validation cohorts, in order to improve the specificity of the proposed thresholds 20 
and evaluate the possible clinical utility of the immune-parameters found. In such ongoing 21 
study, refined grouping strategies will be adopted, in order to define more accurately the 22 
quantitative values of the immune-phenotypic parameters significantly correlated with patient 23 
survival and other clinical parameters. Only if the validation study will confirm this pilot 24 
experience, the immune biomarkers identified in the present study may be considered as 25 
18 
 
additional parameters to be analyzed - beyond the parameters already adopted to perform MPM 1 
diagnosis - in challenging clinical cases.  2 
Of note, this study is the first one aimed to systematically characterize the immune-infiltrate of 3 
pleural fluid and tumor derived from the same patient. Our results indicated that the analysis 4 
of the intratumor immune-infiltrate – better than that of pleural fluid – identifies potential 5 
prognostic factors. Given the high inter-patients and intra-patients variability observed in 6 
MPM, the larger prospective validation study will also clarify if the qualitative and quantitative 7 
differences in the intra-tumor immune-infiltrate may be correlated with specific histological, 8 
cyto-genetic and mutational features. This may contribute to a more accurate patients’ 9 
stratification, for a rationale and personalized immune-therapy of MPM.    10 
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Figure legends 4 
Figure 1. Lymphocyte subtypes present in pleural fluid and tissue of malignant pleural 5 
mesothelioma 6 
Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural 7 
mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from 8 
digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) 9 
were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same 10 
patients were analyzed in parallel. A-C. Percentage of total (CD3+), T-helper (CD3+CD4+)  and 11 
T-cytotoxic (CD3+CD8+) lymphocytes. Data are presented as means±SD. Values of 25th 12 
percentile, median, 75th percentile: pleuritis PF: 52.00, 61.00, 66.00; pleuritis PT: 15.00, 21.00, 13 
26.75; MPM PF: 52.00, 62.00, 71.00; MPM PT: 37.75, 47.00, 58.75; MTS PF: 51.00, 55.00, 14 
64.00; MTS PT: 36.50, 41.00, 51.50 (panel A); pleuritis PF: 39.25, 52.00, 60.50; pleuritis PT: 15 
51.00, 61.00, 67.00; MPM PF: 48.25, 61.00, 70.25; MPM PT: 51.00, 56.00, 71.00; MTS PF: 16 
45.10, 51.50, 60.50; MTS PT: 54.00, 61.00, 67.50 (panel B); pleuritis PF: 2.90, 3.75, 5.98; 17 
pleuritis PT: 30.00, 41.00, 49.00; MPM PF: 25.00, 29.00, 33.00; MPM PT: 12.00, 15.00, 19.00; 18 
MTS PF: 14.50, 20.00, 26.00; MTS PT: 10.50, 11.00, 15.50 (panel C). ***p<0.001: 19 
MPM/MTS vs pleuritis; not significant: MPM vs MTS. D. Disaggregated data of T-cytotoxic 20 
cells percentage in PF and PT from the same patient. Dotted line: 6.3% cut-off value in PF 21 
(false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). E. Percentage of 22 
T-regulatory (Treg; CD4+ CD25+CD127low) cells. Data are presented as means±SD. Values of 23 
25th percentile, median, 75th percentile: pleuritis PF: 0.90, 1.20, 1.50; pleuritis PT: 0.30, 0.50, 24 
0.90; MPM PF: 2.73, 2.95, 3.48; MPM PT: 2.10, 2.80, 3.25; MTS PF: 1.10, 1.25, 1.50; MTS 25 
26 
 
PT: 0.75, 1.10, 1.25. ***p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS. 1 
F. Disaggregated data of Treg cells percentage in PF and PT from the same patient. Dotted 2 
line: 1.4% cut-off value in PF; dashed line: 1.1% cut-off value in PT (false negative: 0%; false 3 
positive: 11%; sensitivity: 100%; specificity: 89%) 4 
Figure 2. Macrophage and myeloid-derived suppressor cell subtypes present in pleural 5 
fluid and pleural tissue of malignant pleural mesothelioma 6 
Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural 7 
mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from 8 
digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) 9 
were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same 10 
patients were analyzed in parallel. A. Percentage of macrophages (CD14+CD68+ cells). Data 11 
are presented as means±SD. Values of 25th percentile, median, 75th percentile: pleuritis PF: 12 
15.00, 19.00, 31.00; pleuritis PT: 21.00, 25.00, 32.00; MPM PF: 49.25, 61.00, 71.00; MPM 13 
PT: 41.75, 55.00, 62.25; MTS PF: 48.25, 54.00, 66.25; MTS PT: 48.50, 65.00, 69.50. *p<0.01, 14 
***p<0.001: MPM/MTS vs pleuritis. B. Disaggregated data of macrophage percentage in PF 15 
and PT from the same patient. Dotted line: 34% cut-off value in PF, dashed line: 35% cut-off 16 
value in PT (false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). C. 17 
Percentage of M2-macrophages (CD68+CD206+Arg1+cells). Data are presented as means±SD. 18 
Values of 25th percentile, median, 75th percentile: pleuritis PF: 17.25, 22.00, 28.00; pleuritis 19 
PT: 23.00, 28.00, 34.50; MPM PF: 45.00, 55.00, 62.25; MPM PT: 56.00, 60.00, 68.25; MTS 20 
PF: 41.25, 44.00, 57.00; MTS PT: 53.00, 64.00, 65.00. ***p<0.001: MPM/MTS vs pleuritis. 21 
D. Disaggregated data of M2-macrophage percentage in PF and PT from the same patient. 22 
Dotted line: 29% cut-off value in PF, dashed line:  36% cut-off value in PT (false negative: 23 
0%; false positive: 0%; sensitivity: 100%; specificity: 100%). E. Percentage of granulocytic 24 
myeloid-derived suppressor cells (Gr-MDSC; CD11b+CD14-CD15+cells). Data are presented 25 
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as means±SD. Values of 25th percentile, median, 75th percentile: pleuritis PF: 2.20, 2.80, 3.68; 1 
pleuritis PT: 2.10, 2.60, 3.10; MPM PF: 11.23, 13.05, 17.73; MPM PT: 11.80, 13.15, 17.03; 2 
MTS PF: 3.28, 5.15, 6.30; MTS PT: 4.80, 5.10, 7.70. ***p<0.001: MPM vs pleuritis; 3 
°°°p<0.001: MPM vs MTS. F. Disaggregated data of Gr-MDSC percentage in PF and PT from 4 
the same patient. Dashed line: 5.1% cut-off value in PF and PT (false negative: 0%; false 5 
positive: 0%; sensitivity: 100%; specificity: 100%). G. Percentage of monocytic myeloid 6 
derived suppressor cells (Mo-MDSC; CD11b+CD14+CD15lowcells). Data are presented as 7 
means±SD. ***p<0.001: MPM vs pleuritis; °°°p<0.001: MPM vs MTS. Values of 25th 8 
percentile, median, 75th percentile: pleuritis PF: 2.10, 2.40, 3.45; pleuritis PT: 2.13, 2.75, 3.18; 9 
MPM PF: 5.90, 8.20, 10.20; MPM PT: 8.10, 9.75, 11.28; MTS PF: 1.30, 2.30, 2.90; MTS PT: 10 
1.90, 2.35, 2.80. H. Disaggregated data of Mo-MDSC percentage in PF and PT from the same 11 
patient. Dotted line: 3.6% cut-off value in PF, dashed line: 4.2% cut-off value in PT (false 12 
negative: 0%; false positive: 11%; sensitivity: 100%; specificity: 89%). 13 
Figure 3. Intratumor myeloid-derived suppressor cells determines CD8+ T-lymphocytes 14 
anergy 15 
1×104 sorted intra-tissue Gr-MDSC and Mo-MDSC derived from pleuritis (n=10), MPM 16 
(n=12) and other tumors metastatizing to pleura (MTS; n=4) were seeded and analyzed after 17 
24 h (panels A-C), or co-cultured (panels D-F) for 6 days with the sorted intra-tissue 18 
CD3+CD8+T-cytotoxic lymphocytes of the corresponding patient (autologous setting). When 19 
indicated, Gr-MDSC and Mo-MDSC from MPM patients were cultured with T-cytotoxic 20 
lymphocytes from pleuritis patients (pleu/MPM setting; n=8). A-C. Intracellular ROS (panel 21 
A) were measured fluorimetrically, nitrite (panel B) and kynurenine (panel C) released in the 22 
supernatants were measured spectrophotometrically. Data are presented as means±SD. Values 23 
of 25th percentile, median, 75th percentile: pleuritis Gr-MDSC: 0.59 0.79, 0.94; pleuritis Mo-24 
MDSC: 0.43, 0.65, 0.80; MPM Gr-MDSC: 2.08, 2.40, 2.78; MPM Mo-MDSC: 1.78, 2.20, 25 
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2.68; MTS Gr-MDSC: 0.61, 0.72, 0.81; MTS Mo-MDSC: 0.43, 0.66, 0.82 (panel A); pleuritis 1 
Gr-MDSC: 1.58, 2.00, 2.45; pleuritis Mo-MDSC: 1.60, 2.10, 2.95; MPM Gr-MDSC: 8.20, 2 
9.75, 12.25; MPM Mo-MDSC: 6.05, 6.85, 8.55; MTS Gr-MDSC: 1.30, 1.75, 2.65; MTS Mo-3 
MDSC: 1.63, 2.15, 2.45 (panel B); pleuritis Gr-MDSC: 0.55, 0.72, 0.82; pleuritis Mo-MDSC: 4 
0.72, 0.87, 1.16; MPM Gr-MDSC: 3.73, 4.14, 4.85; MPM Mo-MDSC: 4.25, 5.26, 5.35; MTS 5 
Gr-MDSC: 0.59, 0.89, 1.19; MTS Mo-MDSC: 0.78, 1.00, 1.24 (panel C). *p<0.01, **p<0.005, 6 
***p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM vs MTS. D-F. The 7 
proliferation of T-cytotoxic lymphocytes (panel D) was measured radiometrically, the 8 
percentage of CD8+CD107a+lymphocytes (panel E) was measured by flow cytometry, the 9 
amount of IFN-γ (panel F) in the supernatants was measured by ELISA. The proliferation of 10 
T-lymphocytes in the absence of anti-CD3/anti-CD28 dynabeads, used as negative control, was 11 
<3500 cpm for all experimental conditions. Data are presented as means±SD. Values of 25th 12 
percentile, median, 75th percentile: pleuritis Gr-MDSC: 18.09, 23.12, 26.03; pleuritis Mo-13 
MDSC: 27.53, 30.4, 34.62; MPM Gr-MDSC:2.42, 4.04, 5.00; MPM Mo-MDSC: 4.03, 5.71, 14 
6.84; MTS Gr-MDSC: 16.66, 22.69, 28.46; MTS Mo-MDSC: 23.27, 31.72, 33.96; pleu/MPM 15 
Gr-MDSC: 5.33, 5.80, 7.19; pleu/MPM Mo-MDSC: 6.44, 8.25, 11.70 (panel D); pleuritis Gr-16 
MDSC:2.08, 2.60, 2.83; pleuritis Mo-MDSC: 2.48, 3.00, 3.25; MPM Gr-MDSC: 0.40, 0.60, 17 
0.80; MPM Mo-MDSC: 0.45, 0.80, 1.05; MTS Gr-MDSC: 1.95, 2.65, 3.05; MTS Mo-MDSC: 18 
2.83, 3.05, 3.65; pleu/MPM Gr-MDSC: 0.53, 0.75, 0.80; pleu/MPM Mo-MDSC: 0.40, 0.65, 19 
0.88 (panel E); pleuritis Gr-MDSC: 409.50, 441, 636.50; pleuritis Mo-MDSC: 459.80, 497.50, 20 
521.00; MPM Gr-MDSC: 111.80, 151.00, 203.30; MPM Mo-MDSC: 147.00, 177.00, 236.00; 21 
MTS Gr-MDSC: 322.00, 463.50, 506.80; MTS Mo-MDSC: 373.80, 480.00, 585.50; 22 
pleu/MPM Gr-MDSC: 168.80, 204.50, 263.80; pleu/MPM Mo-MDSC: 209.80, 298.00, 335.80 23 
(panel F).**p<0.005, ***p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM 24 
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vs MTS in autologous settings; #p<0.01, ###p<0.001: pleu/MPM setting vs pleuritis autologous 1 
setting. 2 
Figure 4. Immune-checkpoint expression in T-lymphocytes contained in pleural fluid and 3 
pleural tissue 4 
Cells collected from pleural fluid of patients with pleuritis (n=63), malignant pleural 5 
mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from 6 
digested pleural tissue of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) were 7 
analyzed by flow cytometry. Data are presented as means±SD. A-B. Percentage of PD-1+T-8 
helper (CD3+CD4+) and T-cytotoxic (CD3+CD8+) lymphocytes. Values of 25th percentile, 9 
median, 75th percentile: pleuritis CD3+CD4+: 2.45, 4.60, 5.60; pleuritis CD3+CD8+: 2.50, 3.90, 10 
5.50; MPM CD3+CD4+: 15.53, 18.30, 22.65; MPM CD3+CD8+: 14.83, 17.65, 21.38; MTS 11 
CD3+CD4+: 7.95, 10.20, 12.30; MTS CD3+CD8+: 7.03, 9.00, 11.33 (panel A); pleuritis 12 
CD3+CD4+: 2.10, 3.15, 4.10; pleuritis CD3+CD8+: 2.03, 2.90, 4.18; MPM CD3+CD4+: 10.20, 13 
12.50, 16.15; MPM CD3+CD8+: 11.28, 15.20, 18.05; MTS CD3+CD4+: 3.60, 4.30, 6.50; MTS 14 
CD3+CD8+: 3.10, 6.20, 8.15 (panel B). ***p<0.001: MPM vs pleuritis; °p<0.01, °°°p<0.001: 15 
MPM vs MTS. C-D. Percentage of LAG-3+T-helper (CD3+CD4+)  and T-cytotoxic 16 
(CD3+CD8+) lymphocytes. Values of 25th percentile, median, 75th percentile: pleuritis 17 
CD3+CD4+: 1.90, 2.80, 4.15; pleuritis CD3+CD8+: 1.90, 2.80, 4.15; MPM CD3+CD4+: 10.83, 18 
13.35, 16.25; MPM CD3+CD8+: 8.83, 10.60, 14.05; MTS CD3+CD4+: 3.88, 7.20, 8.40; MTS 19 
CD3+CD8+: 3.75, 7.15, 8.60 (panel C); pleuritis CD3+CD4+: 1.50, 1.85, 2.10; pleuritis 20 
CD3+CD8+: 1.60, 1.80, 2.18; MPM CD3+CD4+: 8.38, 10.50, 14.28; MPM CD3+CD8+: 8.10, 21 
10.50, 14.10; MTS CD3+CD4+: 3.40, 4.60, 5.40; MTS CD3+CD8+: 2.95, 4.10, 4.65 (panel D). 22 
***p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM vs MTS. E-F. 23 
Percentage of TIM-3+T-helper (CD3+CD4+)  and T-cytotoxic (CD3+CD8+) lymphocytes. 24 
Values of 25th percentile, median, 75th percentile: pleuritis CD3+CD4+:1, 1.80, 2.48; pleuritis 25 
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CD3+CD8+: 0.90, 1.35, 1.70; MPM CD3+CD4+: 6.10, 7.30, 8.40; MPM CD3+CD8+: 6.65, 8.30, 1 
10.70; MTS CD3+CD4+: 2.18, 3.85, 4.43; MTS CD3+CD8+: 1.98, 3.15, 4.13 (panel E); pleuritis 2 
CD3+CD4+: 1.13, 1.50, 2.05; pleuritis CD3+CD8+: 1.20, 1.35, 1.58; MPM CD3+CD4+: 6.18, 3 
8.10, 8.53; MPM CD3+CD8+: 6.78, 9.10, 10.20; MTS CD3+CD4+: 1.25, 1.60, 2.20; MTS 4 
CD3+CD8+: 1.15, 1.40, 1.85 (panel F). ***p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: 5 
MPM vs MTS. G-H. Percentage of CTLA-4+T-helper (CD3+CD4+)  and T-cytotoxic 6 
(CD3+CD8+) lymphocytes. Values of 25th percentile, median, 75th percentile: pleuritis 7 
CD3+CD4+: 1.20, 1.40, 1.90; pleuritis CD3+CD8+: 0.90, 1.30, 1.58; MPM CD3+CD4+: 1.10, 8 
1.60, 1.90; MPM CD3+CD8+: 1.10, 1.20, 1.50; MTS CD3+CD4+: 1.18, 1.50, 2.10; MTS 9 
CD3+CD8+: 1.20, 1.30, 1.80 (panel G); pleuritis CD3+CD4+: 1.10, 1.20, 2.05; pleuritis 10 
CD3+CD8+: 1.25, 1.40, 1.70; MPM CD3+CD4+: 1.30, 1.80, 2.10; MPM CD3+CD8+: 1.20, 1.50, 11 
1.90; MTS CD3+CD4+: 1.45, 1.70, 2.38; MTS CD3+CD8+: 1.13, 1.40, 1.73 (panel H). 12 
Figure 5. Immune-checkpoint ligands expressed in malignant pleural mesothelioma cells 13 
Mesothelial cells collected from patients with pleuritis (n=24), malignant pleural mesothelioma 14 
cells (MPM; n=33) or cells from different tumors metastatizing to pleura (MTS; n=16), were 15 
analyzed by flow cytometry for the expression of PD-L1 (panel A), LAG-3 (panel B), TIM-3 16 
(panel C), GAL-9 (panel D). Data are presented as means±SD. Values of 25th percentile, 17 
median, 75th percentile: pleuritis: 2.55, 3.60, 4.35; MPM: 15.05, 17.25, 22.95; MTS: 5.60, 9.30, 18 
12.70 (panel A); pleuritis: 1.43, 1.95, 2.83; MPM: 7.40, 9.10, 11.25; MTS: 2.40, 4.10, 5.10 19 
(panel B); pleuritis: 1.20, 1.90, 2.73; MPM: 7.35, 8.70, 10.25; MTS: 1.65, 2.40, 5.35 (panel 20 
C); pleuritis: 1.30, 2.40, 6.23; MPM: 13.40, 17.20, 21.50; MTS: 4.70, 7.80, 9.25 (panel 21 
D).***p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS.  22 
31 
 
Table 1. Survival analysis according to the immune-phenotypic parameter characterizing 1 
mesothelioma patients 2 
Immune-population Sample PFS (months) (95% CI) p value OS (months) (95% CI) p value 
CD3+CD8+ low vs CD3+CD8+ high PF 6.3+1.6  vs 6.3+1.0 (5.0-8.3) 0.913 10.0+2.2  vs 10.8+1.1 (8.2-12.7) 0.6927 
Treg low vs Treg high PF 6.0+1.1  vs 7.0+1.6 (4.7-8.1) 0.496 10.8+1.6  vs 9.7+1.4 (8.2-12.7) 0.4347 
M2 low vs M2 high PF 7.0+1.3  vs 5.7+1.0 (4.7-7.8) 0.2851 10.9+1.5  vs 9.8+1.9 (8.2-12.7) 0.7424 
Gr-MDSC low vs Gr-MDSC high PF 7.1+1.1  vs 5.6+1.3 (4.6-8.1) 0.3351 10.6+1.4  vs 10.8+2.2 (8.2.9-13.1) 0.4522 
Mo-MDSC low vs Mo-MDSC high PF 6.8+1.2  vs 5.9+1.4 (4.4-8.1) 0.8755 10.8+1.6  vs 9.4+1.7 (7.9-12.5) 0.5498 
CD4+PD-1+ low vs CD4+PD-1+ high PF 5.7+1.3  vs 7.3+1.1 (4.7-8.1) 0.713 8.6+1.5  vs 12.4+1.6 (8.2-12.7) 0.1126 
CD4+LAG-3+ low vs CD4+LAG-3+ high PF 7.2+1.4  vs 7.3+1.1 (5.0-8.4) 0.4585 9.6+2.5  vs 10.9+1.1 (8.2-12.7) 0.7886 
CD4+TIM-3+ low vs CD4+TIM-3+ high PF 8.1+1.1  vs 5.0+1.3 (4.9-8.4) 0.1047 11.9+1.2  vs 9.1+2.1 (8.4-12.9) 0.5417 
CD8+PD-1+ low vs CD8+PD-1+ high PF 7.2+1.3  vs 6.8+1.2 (5.3-8.8) 0.6309 9.4+2.0  vs 10.0+1.4 (7.6-11.9) 0.9571 
CD8+LAG-3+ low vs CD8+LAG-3+ high PF 6.5+1.4  vs 4.8+0.8 (4.1-7.2) 0.2127 11.0+1.8  vs 10.1+1.9 (8.1-13.0) 0.8569 
CD8+TIM-3+ low vs CD8+TIM-3+ high PF 7.7+1.1  vs 4.3+1.2 (4.31-7.6) 0.0956 11.0+1.6  vs 9.7+1.6 (8.2-12.3) 0.5441 
CD3+CD8+ low vs CD3+CD8+ high PT 7.4+1.0  vs 8.0+1.3 (6.1-9.2) 0.8624 9.6+1.4  vs 10.3+1.3 (8.3-11.9) 0.9594 
Treg low vs Treg high PT 9.1+1.8  vs 4.7+1.4 (6.1-9.3) 0.0172 12.1+1.2  vs 7.6+1.0 (8.3-11.9) 0.0046 
M2 low vs M2 high PT 7.6+1.7  vs 8.8+1.1 (6.4-10.2) 0.8228 10.4+1.4  vs 9.3+1.2 (8.1-11.7) 0.4016 
Gr-MDSC low vs Gr-MDSC high PT 9.1+1.1  vs 5.6+1.0 (5.9-9.2) 0.0427 11.3+1.3  vs 7.5+1.1 (7.6-11.2) 0.037 
Mo-MDSC low vs Mo-MDSC high PT 11.2+1.2  vs 7.3+1.4 (7.7-11.5) 0.0178 11.1+1.7  vs 8.0+1.0 (8.1-11.4) 0.026 
CD4+PD-1+ low vs CD4+PD-1+ high PT 7.9+1.0  vs 7.9+1.7 (6.2-9.5) 0.6616 11.4+1.1  vs 8.3+1.1 (8.5-11.8) 0.043 
CD4+LAG-3+ low vs CD4+LAG-3+ high PT 8.3+1.1  vs 7.0+1.3 (6.1-9.3) 0.364 11.5+1.4  vs 8.0+0.9 (8.0-11.5) 0.0077 
CD4+TIM-3+ low vs CD4+TIM-3+ high PT 6.8+1.6  vs 8.4+0.9 (6.1-9.4) 0.7595 11.7+1.2  vs 7.8+1.2 (8.0-11.7) 0.044 
CD8+PD-1+ low vs CD8+PD-1+ high PT 7.8+1.3  vs 7.9+1.2 (6.2-9.5) 0.9333 10.3+1.3  vs 10.0+1.2 (8.4-11.8) 0.9315 
CD8+LAG-3+ low vs CD8+LAG-3+ high PT 6.7+1.3  vs 8.0+1.1 (5.7-9.0) 0.6298 9.7+1.5  vs 10.6+1.1 (8.3-11.9) 0.9219 
CD8+TIM-3+ low vs CD8+TIM-3+ high PT 6.8+1.7  vs 8.4+0.8 (6.1-9.3) 0.7423 8.5+1.6  vs 10.6+1.2 (8.0-11.6) 0.574 
The median values of CD3+CD8+ lymphocytes, Treg, M2-macrophages, Gr-MDSC, Mo-3 
MDSC, CD4+PD-1+, CD4+LAG-3+, CD4+TIM-3+, CD8+PD-1+, CD8+LAG-3+, CD8+TIM-3+ 4 
cells was calculated in pleural fluid (PF; n=49) and pleural tissue (PT; n=33). Patients were 5 
classified as “low” or “high” if the percentage of each population was low or equal/higher than 6 
the median value. Progression free survival (PFS) and overall survival (OS) probability were 7 
calculated using the Kaplan-Meier method, and expressed as measn±SD (months). CI: 8 
confidence interval. Significant values are indicated by bold characters.   9 
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